Thermo Fisher Scientific (TMO) 10-Q 1 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 28, 2015	Jun. 28, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Thermo Fisher Scientific Inc.
Entity Central Index Key	97745
Document Type	10-Q
Document Period End Date	28-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float		$47,112,558
Entity Common Stock, Shares Outstanding	398,056,940
Entity Stock Trading Symbol	TMO

Consolidated_Balance_Sheet_Una

Consolidated Balance Sheet (Unaudited) (USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Current Assets:
Cash and cash equivalents	$864.60	$1,343.50
Short-term investments	8.4	8.5
Accounts receivable, less allowances of $71.7 and $74.1	2,538	2,473.60
Inventories	1,898.80	1,859.50
Deferred tax assets	299.4	303.3
Other current assets	571.3	551.4
Total current assets	6,180.50	6,539.80
Property, Plant and Equipment, at Cost, Net	2,384.20	2,426.50
Acquisition-related Intangible Assets, Net	13,622.50	14,110.10
Other Assets	937.2	933.1
Goodwill	18,732.90	18,842.60
Total Assets	41,857.30	42,852.10
Current Liabilities:
Short-term obligations and current maturities of long-term obligations	4,160.60	2,212.40
Accounts payable	827.6	820.7
Accrued payroll and employee benefits	486.9	668.9
Accrued income taxes	39.1	165.1
Deferred revenue	332.9	311.9
Other accrued expenses	1,013.90	1,170.80
Total current liabilities	6,861	5,349.80
Deferred Income Taxes	3,222.90	3,430.70
Other Long-term Liabilities	1,162.40	1,171.90
Long-term Obligations	10,696.20	12,351.60
Shareholders' Equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 410,212,776 and 408,461,670 shares issued	410.2	408.5
Capital in excess of par value	11,607.30	11,473.60
Retained earnings	10,732.10	10,406.90
Treasury stock at cost, 12,155,836 and 7,991,782 shares	-988.2	-455.9
Accumulated other comprehensive items	-1,846.60	-1,285
Total shareholders' equity	19,914.80	20,548.10
Total Liabilities & Shareholders' Equity	$41,857.30	$42,852.10

Consolidated_Balance_Sheet_Una1

Consolidated Balance Sheet (Unaudited) (Parenthetical) (USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts Receivable Allowances	$71.70	$74.10
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$100	$100
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000	50,000
Preferred Stock, $100 Par Value - Shares Issued (in shares)	0	0
Common Stock, $1 Par Value - Par Value (in dollars per share)	$1	$1
Common Stock, $1 Par Value - Shares Authorized (in shares)	1,200,000,000	1,200,000,000
Common Stock, $1 Par Value - Shares Issued (in shares)	410,212,776	408,461,670
Treasury Stock at Cost (in shares)	12,155,836	7,991,782

Consolidated_Statement_of_Inco

Consolidated Statement of Income (Unaudited) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Revenues
Product revenues	$3,387.60	$3,375.40
Service revenues	531.2	528.1
Total revenues	3,918.80	3,903.50
Costs and Operating Expenses:
Cost of product revenues	1,720.80	1,933.30
Cost of service revenues	375.5	350.2
Selling, general and administrative expenses	1,137.40	1,177
Research and development expenses	165.8	149.7
Restructuring and other costs (income), net	32	-582.2
Total costs and operating expenses	3,431.50	3,028
Operating Income	487.3	875.5
Other Expense, Net	-105.3	-101.1
Income from Continuing Operations Before Income Taxes	382	774.4
Benefit from (Provision for) Income Taxes	3.1	-231.3
Net Income	$385.10	$543.10
Earnings per Share
Basic (in dollars per share)	$0.97	$1.38
Diluted (in dollars per share)	$0.96	$1.36
Weighted Average Shares
Basic (in millions of shares)	397.8	393.3
Diluted (in millions of shares)	401.4	398.4
Cash Dividends Declared per Common Share (in dollars per share)	$0.15	$0.15

Consolidated_Statement_of_Comp

Consolidated Statement of Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Comprehensive Income (Loss)
Net income	$385.10	$543.10
Other Comprehensive Items:
Currency translation adjustment	-563.1	14.3
Unrealized gains on available-for-sale investments:
Unrealized holding gains arising during the period (net of tax provision of $0.0)	0.1	0
Unrealized gains and losses on hedging instruments:
Unrealized loss on hedging instruments (net of tax benefit of $4.9)	-8	0
Reclassification adjustment for losses included in net income (net of tax benefit of $0.1 and $0.4)	1.1	0.7
Pension and other postretirement benefit liability adjustment:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax provision (benefit) of $2.9 and ($0.6))	6.6	-1.9
Amortization of net loss and prior service benefit included in net periodic pension cost (net of tax benefit of $0.7 and $0.6)	1.7	1.3
Total other comprehensive items	-561.6	14.4
Comprehensive Income (Loss)	($176.50)	$557.50

Consolidated_Statement_of_Comp1

Consolidated Statement of Comprehensive Income (Loss) (Unaudited) (Parenthetical) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Statement of Income and Comprehensive Income (Loss) [Abstract]
Tax provision (benefit) on unrealized holding gains and losses on available-for-sale investments arising during the period	$0
Tax provision (benefit) on unrealized holding gains and losses on hedging instruments arising during the period	-4.9
Tax provision (benefit) on reclassification adjustment for losses on hedging instruments recognized in net income	-0.1	-0.4
Tax provision (benefit) on pension and other postretirement benefit liability adjustments arising during the period	2.9	-0.6
Tax provision (benefit) on amortization of net loss and prior service benefit included in net periodic pension cost	($0.70)	($0.60)

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Operating Activities
Net income	$385.10	$543.10
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	416.3	365.6
Change in deferred income taxes	-102.4	-207
Net gains on sale of businesses	0	-758.5
Non-cash stock-based compensation	28.2	25.2
Tax benefits from stock-based compensation awards	-39.2	-48.4
Non-cash charges for sale of inventories revalued at the date of acquisition	0.5	147.6
Other non-cash expenses, net	15.8	16.5
Changes in assets and liabilities, excluding the effects of acquisitions and dispositions:
Accounts receivable	-124.7	-192.6
Inventories	-81.3	-32.1
Other assets	-37.6	4.2
Accounts payable	34.8	-9.8
Other liabilities	-395.4	267.2
Contributions to retirement plans	-18	-18.8
Net cash provided by continuing operations	82.1	102.2
Net cash used in discontinued operations	-2.1	-1
Net cash provided by operating activities	80	101.2
Investing Activities
Acquisitions, net of cash acquired	-298.6	-13,056.30
Proceeds from sale of businesses, net of cash divested	0	1,056.60
Purchase of property, plant and equipment	-97.2	-104.7
Proceeds from sale of property, plant and equipment	0.6	3.4
Proceeds from sale of investments	2	33
Decrease in restricted cash	0.9	0.1
Other investing activities, net	-2	0
Net cash used in investing activities	-394.3	-12,067.90
Financing Activities
Net proceeds from issuance of long-term debt	0	4,999.80
Increase in commercial paper, net	1,218.90	208.1
Repayment of long-term obligations	-851.4	-600.9
Increase in short-term notes payable	0	5.1
Purchases of company common stock	-500	0
Dividends paid	-60.8	-54.9
Net proceeds from issuance of company common stock	0	2,942
Net proceeds from issuance of company common stock under employee stock plans	60	87.5
Tax benefits from stock-based compensation awards	39.2	48.4
Other financing activities, net	-6.3	0
Net cash (used in) provided by financing activities	-100.4	7,635.10
Exchange Rate Effect on Cash	-64.2	2.8
Decrease in Cash and Cash Equivalents	-478.9	-4,328.80
Cash and Cash Equivalents at Beginning of Period	1,343.50	5,826
Cash and Cash Equivalents at End of Period	$864.60	$1,497.20

Consolidated_Statement_of_Shar

Consolidated Statement of Shareholders' Equity (USD $)	Total	Common Stock [Member]	Capital in Excess of Par Value [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Items [Member]
In Millions, unless otherwise specified
Balance at Dec. 31, 2013	$16,856.10	$369.60	$8,222.60	$8,753.30	($412.20)	($77.20)
Balance (in shares) at Dec. 31, 2013		369.6			-7.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		2.3			-0.3
Issuance of shares under employees' and directors' stock plans	61.4	2.3	89.5		-30.4
Issuance of shares (in shares)		34.9
Issuance of shares	2,942.30	34.9	2,907.40
Stock-based compensation	25.2		25.2
Tax benefit related to employees' and directors' stock plans	48.2		48.2
Dividends declared	-60.1			-60.1
Net income	543.1			543.1
Other comprehensive items	14.4					14.4
Balance at Mar. 29, 2014	20,430.60	406.8	11,292.90	9,236.30	-442.6	-62.8
Balance (in shares) at Mar. 29, 2014		406.8			-7.9
Balance at Dec. 31, 2014	20,548.10	408.5	11,473.60	10,406.90	-455.9	-1,285
Balance (in shares) at Dec. 31, 2014		408.5			-8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares under employees' and directors' stock plans (in shares)		1.7			-0.3
Issuance of shares under employees' and directors' stock plans	35.9	1.7	66.5		-32.3
Stock-based compensation	28.2		28.2
Tax benefit related to employees' and directors' stock plans	39		39
Purchases of company common stock (in shares)					3.9
Purchases of company common stock	-500				-500
Dividends declared	-59.9			-59.9
Net income	385.1			385.1
Other comprehensive items	-561.6					-561.6
Balance at Mar. 28, 2015	$19,914.80	$410.20	$11,607.30	$10,732.10	($988.20)	($1,846.60)
Balance (in shares) at Mar. 28, 2015		410.2			-12.2

Nature_of_Operations_and_Summa

Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 28, 2015
Nature of Operations and Summary of Significant Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting Policies [Text Block]	Note 1. Nature of Operations and Summary of Significant Accounting Policies
	Nature of Operations
	Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. Markets served include pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings.
	Interim Financial Statements
	The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair presentation of the financial position at March 28, 2015, the results of operations for the three-month periods ended March 28, 2015, and March 29, 2014, and the cash flows for the three-month periods ended March 28, 2015, and March 29, 2014. Interim results are not necessarily indicative of results for a full year.
	The consolidated balance sheet presented as of December 31, 2014, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2014 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC).
	Note 1 to the consolidated financial statements for 2014 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the three months ended March 28, 2015.
	Warranty Obligations
	Product warranties are included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows:
					Three Months Ended
				March 28,			March 29,
	(In millions)				2015			2014
	Beginning Balance				$	57.5		$	49.8
		Provision charged to income				17.2			19
		Usage				-18.3			-18.4
		Acquisitions				0.5			7.2
		Adjustments to previously provided warranties, net				-0.1			0.6
		Currency translation				-1.9			-0.4
	Ending Balance				$	54.9		$	57.8
	Inventories
	The components of inventories are as follows:
				March 28,				December 31,
	(In millions)					2015		2014
	Raw Materials				$	459.6		$	441.6
	Work in Process					220.7			207.6
	Finished Goods					1,218.50			1,210.30
	Inventories				$	1,898.80		$	1,859.50
	Property, Plant and Equipment
	Property, plant and equipment consists of the following:
				March 28,				December 31,
	(In millions)					2015		2014
	Land				$	280.2		$	281.8
	Buildings and Improvements					955.6			955.1
	Machinery, Equipment and Leasehold Improvements					2,633.10			2,632.00
	Property, Plant and Equipment, at Cost					3,868.90			3,868.90
	Less: Accumulated Depreciation and Amortization					1,484.70			1,442.40
	Property, Plant and Equipment, at Cost, Net				$	2,384.20		$	2,426.50
	Acquisition-related Intangible Assets
	Acquisition-related intangible assets are as follows:
			28-Mar-15								31-Dec-14
					Accumulated								Accumulated
	(In millions)		Gross			Amortization			Net		Gross			Amortization		Net
	Definite Lived:
		Customer relationships	$	11,725.20		$	-3,510.10		$	8,215.10	$	11,866.80		$	-3,340.60	$	8,526.20
		Product technology		4,785.80			-1,515.20			3,270.60		4,898.10			-1,501.30		3,396.80
		Tradenames		1,300.90			-466.3			834.6		1,333.00			-448.7		884.3
		Other		33.5			-32.9			0.6		34.2			-33.3		0.9
				17,845.40			-5,524.50			12,320.90		18,132.10			-5,323.90		12,808.20
	Indefinite Lived:
		Tradenames		1,234.80			—			1,234.80		1,234.80			—		1,234.80
		In-process research and development		66.8			—			66.8		67.1			—		67.1
				1,301.60			—			1,301.60		1,301.90			—		1,301.90
	Acquisition-related Intangible Assets		$	19,147.00		$	-5,524.50		$	13,622.50	$	19,434.00		$	-5,323.90	$	14,110.10
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2) and the ultimate loss from abandoning leases at facilities being exited (Note 14). Actual results could differ from those estimates.
	Recent Accounting Pronouncements
	In April 2015, the FASB issued new guidance that requires the presentation of debt issuance costs in the balance sheet as a deduction from the carrying amount of the related debt liability, consistent with the current treatment of debt discounts. The guidance is effective for annual reporting periods beginning after December 15, 2015, but early adoption is permitted. The company is currently evaluating the impact the standard will have on its consolidated financial statements.
	In January 2015, the FASB issued new guidance to simplify income statement classification by removing the concept of extraordinary items from U.S. GAAP. As a result, items that are both unusual and infrequent will no longer be separately reported net of tax after continuing operations. The company adopted this guidance effective January 2015. The adoption of this standard in 2015 did not have a material impact on the company’s consolidated financial statements.
	In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The guidance is currently effective for the company in 2017. Early adoption is not permitted. The company is currently evaluating the impact the standard will have on its consolidated financial statements.
	In April 2014, the FASB issued new guidance on reporting discontinued operations and disclosures of disposals. Under the new guidance, only disposals representing a strategic shift that has or will have a major effect on operations will be presented as discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of the company that does not qualify for discontinued operations reporting. The company adopted this guidance effective January 2015. The adoption of this standard in 2015 did not have a material impact on the company’s consolidated financial statements.

Acquisitions_and_Dispositions

Acquisitions and Dispositions	3 Months Ended
	Mar. 28, 2015
Acquisitions and Dispositions Disclosure
Acquisitions and Dispositions [Text Block]	Note 2. Acquisitions
	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.
	Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.
	2015
	In February 2015, the company acquired, within the Life Sciences Solutions segment, Advanced Scientifics, Inc., a North America-based global provider of single-use systems and process equipment for bioprocess production, for approximately $289 million. The acquisition expanded the company’s bioprocessing offerings. Revenues of Advanced Scientifics were approximately $80 million in 2014. The purchase price exceeded the fair value of the identifiable net assets and, accordingly, $118 million was allocated to goodwill, all of which is tax deductible.
	In addition, in 2015, the company acquired, within the Analytical Instruments segment, selected assets of certain existing channel partners for its chromatography and mass spectrometry products, for an aggregate purchase price of $11 million.
	During the first three months of 2015, the company made contingent purchase price payments totaling $8 million for acquisitions completed prior to 2015. The contingent purchase price payments were contractually due to the sellers upon achievement of certain performance criteria at the acquired businesses.
			The components of the purchase price and net assets acquired for 2015 acquisitions are as follows:
	(In millions)				Advanced Scientifics		Other		Total
	Purchase Price
		Cash paid			$	289.1	$	9.6	$	298.7
		Purchase price payable				—		1.3		1.3
		Cash acquired				-0.1		—		-0.1
					$	289	$	10.9	$	299.9
	Net Assets Acquired
		Current assets			$	27.9	$	3.9	$	31.8
		Property, plant and equipment				10.6		—		10.6
		Definite-lived intangible assets:
			Customer relationships			96.1		4.3		100.4
			Product technology			37.3		—		37.3
			Tradenames and other			2.3		—		2.3
		Goodwill				118.1		4.2		122.3
		Other assets				0.2		—		0.2
		Liabilities assumed				-3.5		-1.5		-5
					$	289	$	10.9	$	299.9
	The weighted-average amortization periods for definite-lived intangible assets acquired in 2015 are 16 years for customer relationships, 11 years for product technology and 10 years for tradenames and other. The weighted average amortization period for all definite-lived intangible assets acquired in 2015 is 15 years.
	Unaudited Pro Forma Information
	The company acquired Life Technologies in February 2014. Had the acquisition of Life Technologies been completed as of the beginning of 2013, the company’s pro forma results for the first three months of 2014 would have been as follows:
					Three Months Ended
				March 29,
	(In millions except per share amounts)				2014
	Revenues				$	4,176.40
	Net Income				$	728.5
	Earnings per Share:
		Basic			$	1.83
		Diluted			$	1.81
	These pro forma results of operations have been prepared for comparative purposes only, and they do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the date indicated or that may result in the future.
	The company’s results would not have been materially different from its pro forma results had the company’s other 2014 or 2015 acquisitions occurred at the beginning of 2013 or 2014, respectively.

Business_Segment_Information

Business Segment Information	3 Months Ended
	Mar. 28, 2015
Business Segments
Business Segment Information [Text Block]	Note 3. Business Segment Information
	The company’s financial performance is reported in four segments. A description of each segment follows.
	Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease. These products and services are used by customers in pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.
	Analytical Instruments: provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and other research and industrial markets, as well as the clinical laboratory.
	Specialty Diagnostics: provides a wide range of diagnostic test kits, reagents, culture media, instruments and associated products used to increase the speed and accuracy of diagnoses. These products are used by customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories.
	Laboratory Products and Services: provides virtually everything needed for the laboratory, including a combination of self-manufactured and sourced products and an extensive service offering. These products and services are used by customers in pharmaceutical, biotechnology, academic, government and other research and industrial markets, as well as the clinical laboratory.
	The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.
	Business Segment Information
					Three Months Ended
				March 28,			March 29,
	(In millions)				2015			2014
	Revenues
		Life Sciences Solutions			$	1,019.90		$	835.5
		Analytical Instruments				727.4			769.9
		Specialty Diagnostics				785.2			813.7
		Laboratory Products and Services				1,513.40			1,590.50
		Eliminations				-127.1			-106.1
			Consolidated revenues			3,918.80			3,903.50
	Segment Income (a)
		Life Sciences Solutions				298.7			244.6
		Analytical Instruments				121.7			130.9
		Specialty Diagnostics				214.1			221
		Laboratory Products and Services				222.1			234
			Subtotal reportable segments (a)			856.6			830.5
		Cost of revenues charges				-0.6			-168.5
		Selling, general and administrative charges, net				-7.6			-82.8
		Restructuring and other (costs) income, net				-32			582.2
		Amortization of acquisition-related intangible assets				-329.1			-285.9
			Consolidated operating income			487.3			875.5
		Other expense, net (b)				-105.3			-101.1
		Income from continuing operations before income taxes			$	382		$	774.4
	Depreciation
		Life Sciences Solutions			$	33.5		$	24
		Analytical Instruments				9.3			10.4
		Specialty Diagnostics				17.8			18.8
		Laboratory Products and Services				26.6			26.5
			Consolidated depreciation		$	87.2		$	79.7
	(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.
	(b)	The company does not allocate other expense, net to its segments.

Other_Expense_Net

Other Expense, Net	3 Months Ended
	Mar. 28, 2015
Other Expense, Net Disclosure
Other Expense, Net [Text Block]	Note 4. Other Expense, Net
	The components of other expense, net, in the accompanying statement of income are as follows:
			Three Months Ended
		March 28,			March 29,
	(In millions)		2015			2014
	Interest Income		$	7		$	11.9
	Interest Expense			-108.4			-117.8
	Other Items, Net			-3.9			4.8
	Other Expense, Net		$	-105.3		$	-101.1
	Other Items, Net
	In 2015, other items, net includes costs of $7.5 million associated with entering into interest rate swap arrangements and a $3 million loss on the early extinguishment of debt. In 2014, other items, net includes a $4 million gain from an equity investment.

Stockbased_Compensation_Expens

Stockbased Compensation Expense	3 Months Ended
	Mar. 28, 2015
Stock-based Compensation Expense Disclosure [Abstract]
Stock-based Compensation Expense [Text Block]	Note 5. Stock-based Compensation Expense
		The components of stock-based compensation expense are primarily included in selling, general and
	administrative expenses and include the following:
				Three Months Ended
			March 28,			March 29,
	(In millions)			2015			2014
	Stock Option Awards			$	10.4		$	10.7
	Restricted Unit Awards				17.8			14.5
	Total Stock-based Compensation Expense			$	28.2		$	25.2
	As of March 28, 2015, there was $111 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be recognized through 2019 with a weighted average amortization period of 2.7 years.
	As of March 28, 2015, there was $181 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is expected to be recognized through 2018 with a weighted average amortization period of 2.6 years.
	During the first three months of 2015, the company made equity compensation grants to employees consisting of 0.9 million service- and performance-based restricted stock units and options to purchase 1.7 million shares.
	Certain pre-acquisition equity awards of Life Technologies were converted to rights to receive future cash payments over the remaining vesting period. In addition to stock-based compensation, which is included in the above table, in the three-month periods ended March 28, 2015 and March 29, 2014, the company recorded expense for cash-in-lieu of equity of $8.4 million and $7.1 million, respectively, related to these arrangements.

Pension_and_Other_Postretireme

Pension and Other Postretirement Benefit Plans	3 Months Ended
	Mar. 28, 2015
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	Note 6. Pension and Other Postretirement Benefit Plans
	Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The costs of the postretirement healthcare programs are generally funded on a self-insured and insured-premium basis.
		Net periodic benefit costs for the company’s defined benefit pension plans include the following components:
				Three Months Ended
			March 28,			March 29,
	(In millions)			2015			2014
	Service Cost-Benefits Earned			$	6.2		$	4.6
	Interest Cost on Benefit Obligation				19.4			20.1
	Expected Return on Plan Assets				-23.3			-21.1
	Amortization of Actuarial Net Loss				2.3			1.9
	Net Periodic Benefit Cost			$	4.6		$	5.5

Income_Taxes

Earnings Per Share	3 Months Ended
	Mar. 28, 2015
Earnings per Share
Earnings per Share [Text Block]	Note 8. Earnings per Share
				Three Months Ended
			March 28,			March 29,
	(In millions except per share amounts)			2015			2014
	Net Income			$	385.1		$	543.1
	Basic Weighted Average Shares				397.8			393.3
	Plus Effect of:
		Equity forward arrangement			—			0.7
		Stock options and restricted units			3.6			4.4
	Diluted Weighted Average Shares				401.4			398.4
	Basic Earnings per Share			$	0.97		$	1.38
	Diluted Earnings per Share			$	0.96		$	1.36
	Options to purchase 4.0 million and 2.4 million shares of common stock were not included in the computation of diluted earnings per share for first three months of 2015 and 2014, respectively, because their effect would have been antidilutive.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Mar. 28, 2015
Earnings per Share
Earnings per Share [Text Block]	Note 8. Earnings per Share
				Three Months Ended
			March 28,			March 29,
	(In millions except per share amounts)			2015			2014
	Net Income			$	385.1		$	543.1
	Basic Weighted Average Shares				397.8			393.3
	Plus Effect of:
		Equity forward arrangement			—			0.7
		Stock options and restricted units			3.6			4.4
	Diluted Weighted Average Shares				401.4			398.4
	Basic Earnings per Share			$	0.97		$	1.38
	Diluted Earnings per Share			$	0.96		$	1.36
	Options to purchase 4.0 million and 2.4 million shares of common stock were not included in the computation of diluted earnings per share for first three months of 2015 and 2014, respectively, because their effect would have been antidilutive.

Debt_and_Other_Financing_Arran

Debt and Other Financing Arrangements	3 Months Ended
	Mar. 28, 2015
Debt And Other Financing Arrangements Disclosure [Abstract]
Debt and Other Financing Arrangements [Text Block]	Note 9. Debt and Other Financing Arrangements
			Effective
			Interest Rate at
			March 28,	March 28,			December 31,
	(Dollars in millions)		2015		2015		2014
	Commercial Paper		0.83%		$	1,220.70	$	—
	Term Loan		1.64%			1,175.00		1,275.00
	4.40% 5-Year Senior Notes, Due 3/1/2015					—		500
	3.20% 5-Year Senior Notes, Due 5/1/2015		1.55%			450		450
	5.00% 10-Year Senior Notes, Due 6/1/2015					—		250
	3.50% 5-Year Senior Notes, Due 1/15/2016		1.06%			400		400
	3.20% 5-Year Senior Notes, Due 3/1/2016		3.21%			900		900
	2.25% 5-Year Senior Notes, Due 8/15/2016		2.29%			1,000.00		1,000.00
	1.30% 3-Year Senior Notes, Due 2/1/2017		0.85%			900		900
	1.85% 5-Year Senior Notes, Due 1/15/2018		1.85%			500		500
	2.40% 5-Year Senior Notes, Due 2/1/2019		2.44%			900		900
	6.00% 10-Year Senior Notes, Due 3/1/2020		2.98%			750		750
	4.70% 10-Year Senior Notes, Due 5/1/2020		3.23%			300		300
	5.00% 10-Year Senior Notes, Due 1/15/2021		3.25%			400		400
	4.50% 10-Year Senior Notes, Due 3/1/2021		3.03%			1,000.00		1,000.00
	3.60% 10-Year Senior Notes, Due 8/15/2021		2.52%			1,100.00		1,100.00
	3.30% 7-Year Senior Notes, Due 2/15/2022		3.30%			800		800
	3.15% 10-Year Senior Notes, Due 1/15/2023		3.21%			800		800
	4.15% 10-Year Senior Notes, Due 2/1/2024		4.07%			1,000.00		1,000.00
	2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)		2.03%			696.9		774.3
	5.30% 30-Year Senior Notes, Due 2/1/2044		5.30%			400		400
	Other					21.8		23.2
	Total Borrowings at Par Value					14,714.40		14,422.50
		Fair Value Hedge Accounting Adjustments				11.2		-0.5
		Unamortized Premium (Discount), Net				131.2		142
	Total Borrowings at Carrying Value					14,856.80		14,564.00
		Less: Short-term Obligations and Current Maturities				4,160.60		2,212.40
	Long-term Obligations				$	10,696.20	$	12,351.60
	The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discount or amortization of any premium and, if applicable, adjustments related to hedging.
	See Note 12 for fair value information pertaining to the company’s long-term obligations.
	Credit Facilities
	The company has a revolving credit facility with a bank group that provides for up to $2.00 billion of unsecured multi-currency revolving credit. The facility expires in July 2018. The agreement calls for interest at either a LIBOR-based rate or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for financings of this type. The financial covenant requires the company to maintain a Consolidated Leverage Ratio of debt to EBITDA (as defined in the agreement) below 4.0 to 1.0, decreasing to 3.5 to 1.0 by August 2015, and an Interest Coverage Ratio of EBITDA (as defined in the agreement) to interest expense of 3.0 to 1.0. The credit agreement permits the company to use the facility for working capital; acquisitions; repurchases of common stock, debentures and other securities; the refinancing of debt; and general corporate purposes. The credit agreement allows for the issuance of letters of credit, which reduces the amount available for borrowing. If the company borrows under this facility, it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of March 28, 2015, no borrowings were outstanding under the facility, although available capacity was reduced by approximately $59 million as a result of outstanding letters of credit.
	Commercial Paper Program
	The company has a U.S. commercial paper program pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Maturities may not exceed 397 days from the date of issue and the CP Notes rank pari passu with all of the company’s other unsecured and unsubordinated indebtedness. CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. CP Notes are issued at a discount from par, or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis. As of March 28, 2015, outstanding borrowings under this program were $1.22 billion, with a weighted average remaining period to maturity of 46 days.
	Term Loan
	In connection with the acquisition of Life Technologies, the company entered into an unsecured term loan agreement. The term loan agreement calls for interest at either a LIBOR-based rate or a rate based on the prime lending rate of the agent bank, at the company’s option. The term loan agreement contains affirmative, negative and financial covenants, and events of default customary for financings of this type. The financial covenants require the company to maintain a Consolidated Leverage Ratio of debt to EBITDA (as defined in the agreements) below 4.0 to 1.0, decreasing to 3.5 to 1.0 by August 2015, and a minimum interest coverage ratio of 3.0 to 1.0. As of March 28, 2015, outstanding borrowings under the term loan agreement were $1.18 billion. The company is required to make minimum periodic payments through March 2016. Borrowings may be prepaid without penalty.
	Senior Notes
	Interest on the euro-denominated 2.00% Senior Notes due 2025 is payable annually. Interest on each of the other senior notes is payable semi-annually. Each of the notes may be redeemed at any time at a redemption price of 100% of the principal amount plus a specified make-whole premium plus accrued interest. The company is subject to certain affirmative and negative covenants under the indentures governing the senior notes, the most restrictive of which limits the ability of the company to pledge principal properties as security under borrowing arrangements.
	In March 2015, the company paid its 5% Senior Notes due June 1, 2015, and recorded a charge of $3 million for the early extinguishment of this debt.
	Interest Rate Swap Arrangements
	In February 2015, the company entered into LIBOR-based interest rate swap arrangements with various banks on its outstanding 4.70% Senior Notes due May 1, 2020, 4.50% Senior Notes due March 1, 2021 and 3.60% Senior Notes due August 15, 2021. The aggregate amounts of the swaps are equal to the principal amounts of the notes and the payment dates of the swaps coincide with the interest payment dates of the notes. The swap contracts provide for the company to pay a variable interest rate of one-month LIBOR plus a spread of 3.156% (3.3279% at March 28, 2015) and receive a fixed rate of 4.70% on the 4.70% Notes; to pay a variable interest rate of one-month LIBOR plus a spread of 2.868% (3.0399% at March 28, 2015) and receive a fixed rate of 4.50% on the 4.50% Notes; and to pay a variable interest rate of one-month LIBOR plus a spread of 1.937% (2.1115% at March 28, 2015) and receive a fixed rate of 3.60% on the 3.60% Notes. The variable interest rates reset monthly. The swaps have been accounted for as fair value hedges of the notes. See Note 12 for additional information.
	In 2013, upon the issuance of $900 million principal amount of 1.30% Senior Notes due 2017, the company entered into LIBOR-based interest rate swap arrangements with various banks. The aggregate amount of the swaps is equal to the principal amount of the 1.30% Notes and the payment dates of the swaps coincide with the payment dates of the 1.30% Notes. The swap contracts provide for the company to pay a variable interest rate of one-month LIBOR plus a spread of 0.6616% (0.8335% at March 28, 2015) and to receive a fixed rate of 1.30%. The variable interest rate resets monthly. The swaps have been accounted for as a fair value hedge of the 1.30% Notes. See Note 12 for additional information.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 28, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 10. Commitments and Contingencies
	Environmental Matters
	The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates estimates based upon several factors, including reports prepared by environmental specialists and management’s knowledge of and experience with these environmental matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At March 28, 2015 and December 31, 2014, the company’s total environmental liability was approximately $31 million and $32 million, respectively. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations or cash flows.
	Litigation and Related Contingencies
	There are various lawsuits and claims pending against the company involving product liability, intellectual property, employment, and contractual issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, and, with respect to certain pending litigation or claims where no liability has been accrued, to make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows.
	Product Liability, Workers Compensation and Other Personal Injury Matters
	For product liability, workers compensation and other personal injury matters, the company accrues the most likely amount or at least the minimum of the range of possible loss when a range of possible loss can be estimated. The company records estimated amounts due from insurers related to certain product liabilities as an asset. Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary materially. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.
	Intellectual Property Matters
	On February 3, 2014, the company acquired Life Technologies. Life Technologies and its subsidiaries are party to several lawsuits in which plaintiffs claim infringement of their intellectual property, including the following:
	On June 6, 2004, Enzo Biochem, Enzo Life Sciences and Yale University filed a complaint against Life Technologies in United States District Court for the District of Connecticut. The plaintiffs allege patent infringement by Applera’s labeled DNA terminator products used in DNA sequencing and fragment analysis. The plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief. In November 2012, the jury awarded damages of $48.5 million. Prejudgment interest of $12.4 million was also granted. The $60.9 million judgment and interest was accrued by Life Technologies and the liability was assumed by the company as of the date of the acquisition. In March 2015 the United States Court of Appeals for the Federal Circuit vacated the judgment and returned the case to the District Court for further proceedings. In April 2015, the plaintiff filed a petition for rehearing. The company has maintained the $60.9 million accrual, pending appeals.
	On January 30, 2012, Enzo Life Sciences filed a complaint against Life Technologies in United States District Court for the District of Delaware. The plaintiff alleges patent infringement by Life Technologies’ Taqman probes and assays, Dynabead oligo-dT beads, NCode oligonucleotide array products, Ion Torrent beads and chips and SOLiD beads and chips. The plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest and injunctive relief.
	On May 26, 2010, Promega Corp. & Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften EV filed a complaint against Life Technologies in the United States District Court for the Western District of Wisconsin. The plaintiffs allege patent infringement by sales and uses of Applied Biosystems’ short tandem repeat DNA identification products outside the scope of a 2006 license agreement. The plaintiff sought damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief. Although a jury initially found willful infringement and assessed damages at $52 million, the District Court subsequently overturned the verdict on the grounds that the plaintiff had failed to prove infringement. The District Court entered judgment in favor of Life Technologies; and plaintiffs and Life Technologies filed cross-appeals with the United States Court of Appeals for the Federal Circuit. The $52 million award was accrued by Life Technologies and the liability was assumed by the company as of the date of the acquisition. On December 15, 2014, the Court of Appeals issued a decision invalidating four of the plaintiffs’ patents, but finding infringement by Life Technologies of the remaining fifth patent. The Court of Appeals also ordered a new trial on damages in the District Court.
	On December 27, 2011, Illumina Inc. filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging infringement of a patent relating to methods for making bead arrays by Ion Torrent’s semiconductor sequencing systems. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, pre- and post-judgment interest, and injunctive relief.
	On April 26, 2012, Esoterix Genetic Laboratories filed a complaint against Life Technologies in the United States District Court for the Middle District of North Carolina alleging infringement of patents relating to detection of subpopulations of cells with mutated sequences and multiplexed DNA amplification by Life Technologies’ OpenArray systems, next generation SOLiD sequencing system, and Ion Torrent semiconductor sequencing systems. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief.
	On October 31, 2012, Esoterix Genetic Laboratories and The Johns Hopkins University filed a complaint against Life Technologies in the United States District Court for the Middle District of North Carolina alleging infringement of patents relating to methods of determining a ratio of genetic sequences in a population of genetic sequences and methods of determining allelic imbalances in a biological sample by Life Technologies’ OpenArray systems, next generation SOLiD sequencing system, and Ion Torrent semiconductor sequencing systems. Plaintiffs seek damages for alleged willful infringement, attorneys’ fees, costs, prejudgment interest, and injunctive relief.
	On June 3, 2013, Unisone Strategic IP filed a complaint against Life Technologies in the United States District Court for the Southern District of California alleging patent infringement by Life Technologies’ supply chain management system software, which operates with product “supply centers” installed at customer sites. Plaintiff seeks damages for alleged willful infringement, attorneys’ fees, costs, and injunctive relief.

Comprehensive_Income_and_Share

Comprehensive Income and Shareholders Equity	3 Months Ended
	Mar. 28, 2015
Comprehensive Income and Shareholders Equity Disclosure [Abstract]
Comprehensive Income and Shareholders Equity [Text Block]	Note 11. Comprehensive Income and Shareholders’ Equity
	Comprehensive Income (Loss)
	Comprehensive income (loss) combines net income and other comprehensive items. Other comprehensive items represent certain amounts that are reported as components of shareholders’ equity in the accompanying balance sheet.
			Changes in each component of accumulated other comprehensive items, net of tax are as follows:
	(In millions)				Currency Translation Adjustment		Unrealized Gains (Losses) on Available-for-Sale Investments			Unrealized Gains (Losses) on Hedging Instruments			Pension and Other Postretirement Benefit Liability Adjustment		Total
	Balance at December 31, 2014				$	-1,070.60	$	1.3		$	-20.9		$	-194.8	$	-1,285.00
		Other comprehensive income (loss) before reclassifications				-563.1		0.1			-8			6.6		-564.4
		Amounts reclassified from accumulated other comprehensive items				—		—			1.1			1.7		2.8
			Net other comprehensive items			-563.1		0.1			-6.9			8.3		-561.6
	Balance at March 28, 2015				$	-1,633.70	$	1.4		$	-27.8		$	-186.5	$	-1,846.60
			The amounts reclassified out of accumulated other comprehensive items are as follows:
										Three Months Ended
						Affected Line Item in the			March 28,			March 29,
	(In millions)					Statement of Income				2015			2014
	Amounts Reclassified From Accumulated Other Comprehensive Items
		Unrealized gains and losses on hedging instruments:
			Realized loss on interest rate swaps and locks			Other Expense, Net				$	1.2		$	1.1
			Tax benefit			Provision for Income Taxes					-0.1			-0.4
											1.1			0.7
		Pension and other postretirement benefit liability adjustment:
			Amortization of actuarial losses			Net Periodic Benefit Cost -					2.4			1.9
						see Note 6 for details
				Total before tax							2.4			1.9
			Tax benefit			Provision for Income Taxes					-0.7			-0.6
											1.7			1.3
				Total reclassifications						$	2.8		$	2

Fair_Value_Measurements_and_Fa

Fair Value Measurements and Fair Value Of Financial Instruments	3 Months Ended
	Mar. 28, 2015
Fair Value Measurements and Fair Value of Financial Instruments Disclosure
Fair Value Measurements and Fair Value of Financial Instruments [Text Block]	Note 12. Fair Value Measurements and Fair Value of Financial Instruments
	Fair Value Measurements
	The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2015. The company’s financial assets and liabilities carried at fair value are primarily comprised of investments in money market funds; derivative contracts, insurance contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding deferred compensation and retirement liabilities; and acquisition-related contingent consideration.
	The fair value accounting guidance requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.
	Level 3: Inputs are unobservable data points that are not corroborated by market data.
			The following table presents information about the company’s financial assets and liabilities measured at fair
	value on a recurring basis as of March 28, 2015:
				March 28,				Quoted Prices in Active Markets			Significant Other Observable Inputs		Significant Unobservable Inputs
	(In millions)				2015			(Level 1)			(Level 2)		(Level 3)
	Assets
		Cash equivalents			$	22.7		$	22.7		$	—	$	—
		Bank time deposits				8.4			8.4			—		—
		Investments in mutual funds, unit trusts and other    similar instruments				7.9			7.9			—		—
		Insurance contracts				102			—			102		—
		Derivative contracts				16.1			—			16.1		—
			Total Assets		$	157.1		$	39		$	118.1	$	—
	Liabilities
		Derivative contracts			$	26.3		$	—		$	26.3	$	—
		Contingent consideration				21			—			—		21
			Total Liabilities		$	47.3		$	—		$	26.3	$	21
			The following table presents information about the company’s financial assets and liabilities measured at fair
	value on a recurring basis as of December 31, 2014:
				December 31,				Quoted Prices in Active Markets			Significant Other Observable Inputs		Significant Unobservable Inputs
	(In millions)				2014			(Level 1)			(Level 2)		(Level 3)
	Assets
		Cash equivalents			$	617.3		$	617.3		$	—	$	—
		Bank time deposits				8.5			8.5			—		—
		Investments in mutual funds, unit trusts and other    similar instruments				8.7			8.7			—		—
		Insurance contracts				102.5			—			102.5		—
		Derivative contracts				20.2			—			20.2		—
			Total Assets		$	757.2		$	634.5		$	122.7	$	—
	Liabilities
		Derivative contracts			$	10.4		$	—		$	10.4	$	—
		Contingent consideration				29.6			—			—		29.6
			Total Liabilities		$	40		$	—		$	10.4	$	29.6
	The company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company determines the fair value of acquisition-related contingent consideration based on assessment of the probability that the company would be required to make such future payment. Changes to the fair value of contingent consideration are recorded in selling, general and administrative expense. The following table provides a rollforward of the fair value, as determined by Level 3 inputs, of the contingent consideration.
				Three Months Ended
			March 28,			March 29,
	(In millions)			2015			2014
	Contingent Consideration
		Beginning Balance		$	29.6		$	5.1
		Acquisition			—			29.1
		Payments			-8			-1.1
		Change in fair value included in earnings			-0.5			—
		Currency translation			-0.1			—
		Ending Balance		$	21		$	33.1
	The notional amounts of derivative contracts outstanding, consisting of interest rate swaps and currency exchange contracts, totaled $6.25 billion and $3.74 billion at March 28, 2015 and December 31, 2014, respectively.
	While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the consolidated balance sheet. The following tables present the fair value of derivative instruments in the consolidated balance sheet and statement of income.
					Fair Value – Assets						Fair Value – Liabilities
				March 28,				December 31,		March 28,			December 31,
	(In millions)				2015			2014			2015		2014
	Derivatives Designated as Hedging Instruments
		Interest rate swaps (a)			$	3.5		$	—		$	13.4	$	3.7
	Derivatives Not Designated as Hedging Instruments
		Currency exchange contracts (b)				12.6			20.2			12.9		6.7
	(a)		The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities.
	(b)		The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses.
							Gain (Loss) Recognized
							Three Months Ended
							March 28,		March 29,
	(In millions)							2015			2014
	Derivatives Designated as Fair Value Hedges
	Interest rate swaps - effective portion					$	6.7		$	1.1
	Interest rate swaps - ineffective portion (a)						-7			0.7
Derivatives Not Designated as Fair Value Hedges
	Currency exchange contracts
		Included in cost of revenues				$	13.4		$	0.8
		Included in other expense, net					119.9			0.7
(a)		The ineffective portion of the loss recognized on interest rate swaps during the three months ended March 28, 2015 includes $7.5 million of costs associated with entering into the swap arrangements.
Gains and losses recognized on currency exchange contracts and the effective portion of interest rate swaps are included in the consolidated statement of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions. Gains and losses recognized on the ineffective portion of interest rate swaps are included in other expense, net in the accompanying statement of income.
The company also uses foreign currency-denominated debt to partially hedge its net investments in foreign operations against adverse movements in exchange rates. The company’s euro-denominated 2.00% Senior Notes, due 2025, have been designated as, and are effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in currency translation adjustment within other comprehensive income and shareholders’ equity. In the first three months of 2015, the currency translation adjustment component of other comprehensive income includes pre-tax net gains of $77.1 million from the euro-denominated notes.
Cash Flow Hedge Arrangements
In February 2015, the company entered into interest rate swap arrangements to mitigate the risk of interest rates rising prior to completion of a debt offering in 2016. Based on the company’s conclusion that a debt offering is probable as a result of debt maturing in 2016 and that such debt would carry semi-annual interest payments over a 10-year term, the swaps hedge the cash flow risk for each of the semi-annual fixed-rate interest payments on $1.00 billion of principal amount of the planned 10-year fixed-rate debt issue. The hedge will be terminated upon completion of a debt offering in 2016. The fair value of the hedge at that time will be recorded to accumulated other comprehensive items within shareholders’ equity and will be amortized to interest expense over the term of the debt. The change in the fair value of the hedge, $8.0 million, net of tax, as of March 28, 2015, was classified as a decrease to accumulated other comprehensive items.
Fair Value of Other Financial Instruments
		The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:
				28-Mar-15						31-Dec-14
				Carrying			Fair			Carrying		Fair
(In millions)				Value			Value			Value		Value
Notes Receivable				$	8.8		$	8.8		$	8.3	$	8.3
Debt Obligations:
	Senior notes			$	12,439.30		$	12,897.10		$	13,265.80	$	13,590.60
	Term loan				1,175.00			1,175.00			1,275.00		1,275.00
	Commercial paper				1,220.70			1,220.70			—		—
	Other				21.8			21.8			23.2		23.2
				$	14,856.80		$	15,314.60		$	14,564.00	$	14,888.80
		The fair value of debt obligations was determined based on quoted market prices and on borrowing rates
available to the company at the respective period ends which represent level 2 measurements.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	3 Months Ended
	Mar. 28, 2015
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Text Block]	Note 13. Supplemental Cash Flow Information
				Three Months Ended
			March 28,			March 29,
	(In millions)			2015			2014
	Non-cash Activities
		Fair value of assets of acquired businesses		$	305		$	19,640.10
		Cash paid for acquired businesses			-298.7			-13,528.90
		Liabilities assumed of acquired businesses		$	6.3		$	6,111.20
		Declared but unpaid dividends		$	61		$	61.1
		Issuance of stock upon vesting of restricted stock units		$	76.7		$	73.6

Restructuring_and_Other_Costs_

Restructuring and Other Costs (Income), Net	3 Months Ended
	Mar. 28, 2015
Restructuring And Other Costs, Net Disclosure
Restructuring and Other Costs, Net [Text Block]	Note 14. Restructuring and Other Costs, Net
	Restructuring and other costs in the first three months of 2015 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, including the closure and consolidation of operations within several facilities in the U.S., Europe and Asia. In the first three months of 2015, severance actions associated with facility consolidations and cost reduction measures affected approximately 1% of the company’s workforce.
	As of May 1, 2015, the company has identified restructuring actions that will result in additional charges of approximately $70 million, primarily in the remainder of 2015 which will be recorded when specified criteria are met, such as abandonment of facilities.
	First Three Months of 2015
	During the first three months of 2015, the company recorded net restructuring and other costs by segment as follows:
	(In millions)		Cost of Revenues			Selling, General and Administrative Expenses			Restructuring and Other Costs, Net			Total
	Life Sciences Solutions		$	0.5		$	6.1		$	22.7		$	29.3
	Analytical Instruments			—			—			5.6			5.6
	Specialty Diagnostics			0.1			—			2.8			2.9
	Laboratory Products and Services			—			-0.5			0.9			0.4
	Corporate			—			2			—			2
			$	0.6		$	7.6		$	32		$	40.2
	The components of net restructuring and other costs by segment are as follows:
	Life Sciences Solutions
	In the first three months of 2015, the Life Sciences Solutions segment recorded $29.3 million of net restructuring and other charges. The segment recorded charges to cost of revenues of $0.5 million primarily for sales of inventories revalued at the date of acquisition; $6.1 million of charges to selling, general and administrative expenses for third-party transaction and integration costs related to the acquisitions of Life Technologies and Advanced Scientifics; and $22.7 million of restructuring and other costs, net, $22.5 million of which were cash costs. These costs included $5.0 million of cash compensation contractually due to employees of an acquired business on the date of acquisition; $0.9 million of charges associated with a previous sale of a business; and $16.6 million of costs associated with headcount reductions and facility consolidations in the U.S. and Europe, including $14.7 million for severance, $0.7 million of abandoned facility costs, and $1.2 million of other cash costs, including retention and outplacement costs. The segment also recorded $0.2 million of non-cash charges associated with restructuring actions.
	Analytical Instruments
	In the first three months of 2015, the Analytical Instruments segment recorded $5.6 million of net restructuring and other charges, all of which were cash costs associated with headcount reductions, abandoned facility costs and other expenses associated with facility consolidations.
	Specialty Diagnostics
	In the first three months of 2015, the Specialty Diagnostics segment recorded $2.9 million of net restructuring and other charges, primarily $2.8 million of cash costs for employee severance and other costs associated with headcount reductions.
	Laboratory Products and Services
	In the first three months of 2015, the Laboratory Products and Services segment recorded $0.4 million of net restructuring and other charges. The segment recorded $0.5 million of income to selling, general and administrative expenses for changes in estimates of contingent consideration and $0.9 million of other costs, net. These other costs were primarily cash costs for employee severance associated with headcount reductions.
	Corporate
	In the first three months of 2015, the company recorded $2.0 million of net restructuring and other charges, all of which were selling, general and administrative charges associated with accelerated depreciation on information systems to be abandoned due to integration synergies.
	The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
							Abandonment
	(In millions)				Severance			of Excess Facilities			Other (a)			Total
	Pre-2014 Restructuring Plans
		Balance At December 31, 2014			$	6.2		$	7.5		$	1.8		$	15.5
		Costs incurred in 2015 (b)				0.3			0.2			0.1			0.6
		Reserves reversed				—			—			—			—
		Payments				-1.7			-0.8			-0.5			-3
		Currency translation				-0.3			-0.2			-0.2			-0.7
		Balance At March 28, 2015			$	4.5		$	6.7		$	1.2		$	12.4
	2014 Restructuring Plans
		Balance At December 31, 2014			$	31.5		$	2.3		$	4.1		$	37.9
		Costs incurred in 2015 (b)				4.4			0.7			3.3			8.4
		Reserves reversed				-4.6			—			-1.1			-5.7
		Payments				-20.6			-2.4			-4			-27
		Currency translation				-0.7			—			-0.1			-0.8
		Balance At March 28, 2015			$	10		$	0.6		$	2.2		$	12.8
	2015 Restructuring Plans
		Costs incurred in 2015 (b)			$	21.6		$	0.1		$	0.9		$	22.6
		Payments				-11.1			-0.1			-0.4			-11.6
		Currency translation				0.3			—			—			0.3
		Balance At March 28, 2015			$	10.8		$	—		$	0.5		$	11.3
	Other includes cash charges for relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
	Excludes $5.0 million of cash compensation contractually due to employees of an acquired business on the date of acquisition; $0.9 million of charges associated with a previous sale of a business; and an aggregate of $0.2 million of non-cash charges, net, which are detailed by segment above.
	The company expects to pay accrued restructuring costs as follows: severance, employee-retention obligations and other costs primarily through 2015 and abandoned-facility payments, over lease terms expiring through 2020.

Nature_of_Operations_and_Summa1

Nature of Operations and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 28, 2015
Nature of Operations and Summary of Significant Accounting Policies [Abstract]
Use of Estimates [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2) and the ultimate loss from abandoning leases at facilities being exited (Note 14). Actual results could differ from those estimates.

Acquisitions_and_Dispositions_

Acquisitions and Dispositions (Policies)	3 Months Ended
	Mar. 28, 2015
Acquisitions and Dispositions Disclosure
Business Combinations Policy [Policy Text Block]	The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.
	Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.

Pension_and_Other_Postretireme1

Pension and Other Postretirement Benefit Plans (Policies)	3 Months Ended
	Mar. 28, 2015
General Discussion of Pension and Other Postretirement Benefits [Abstract]
Pension and Other Postretirement Plans, Policy [Policy Text Block]	Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement healthcare programs at several acquired businesses where certain employees are eligible to participate. The costs of the postretirement healthcare programs are generally funded on a self-insured and insured-premium basis.

Nature_of_Operations_and_Summa2

Nature of Operations and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 28, 2015
Nature of Operations and Summary of Significant Accounting Policies [Abstract]
Warranty Obligations [Table Text Block]	Warranty Obligations
	Product warranties are included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of standard product warranty obligations are as follows:
					Three Months Ended
				March 28,			March 29,
	(In millions)				2015			2014
	Beginning Balance				$	57.5		$	49.8
		Provision charged to income				17.2			19
		Usage				-18.3			-18.4
		Acquisitions				0.5			7.2
		Adjustments to previously provided warranties, net				-0.1			0.6
		Currency translation				-1.9			-0.4
	Ending Balance				$	54.9		$	57.8
Inventories [Table Text Block]	Inventories
	The components of inventories are as follows:
				March 28,				December 31,
	(In millions)					2015		2014
	Raw Materials				$	459.6		$	441.6
	Work in Process					220.7			207.6
	Finished Goods					1,218.50			1,210.30
	Inventories				$	1,898.80		$	1,859.50
Property, Plant and Equipment [Table Text Block]	Property, Plant and Equipment
	Property, plant and equipment consists of the following:
				March 28,				December 31,
	(In millions)					2015		2014
	Land				$	280.2		$	281.8
	Buildings and Improvements					955.6			955.1
	Machinery, Equipment and Leasehold Improvements					2,633.10			2,632.00
	Property, Plant and Equipment, at Cost					3,868.90			3,868.90
	Less: Accumulated Depreciation and Amortization					1,484.70			1,442.40
	Property, Plant and Equipment, at Cost, Net				$	2,384.20		$	2,426.50
Finite-Lived Acquisition-related Intangible Assets [Table Text Block]	Acquisition-related Intangible Assets
	Acquisition-related intangible assets are as follows:
			28-Mar-15								31-Dec-14
					Accumulated								Accumulated
	(In millions)		Gross			Amortization			Net		Gross			Amortization		Net
	Definite Lived:
		Customer relationships	$	11,725.20		$	-3,510.10		$	8,215.10	$	11,866.80		$	-3,340.60	$	8,526.20
		Product technology		4,785.80			-1,515.20			3,270.60		4,898.10			-1,501.30		3,396.80
		Tradenames		1,300.90			-466.3			834.6		1,333.00			-448.7		884.3
		Other		33.5			-32.9			0.6		34.2			-33.3		0.9
				17,845.40			-5,524.50			12,320.90		18,132.10			-5,323.90		12,808.20
	Indefinite Lived:
		Tradenames		1,234.80			—			1,234.80		1,234.80			—		1,234.80
		In-process research and development		66.8			—			66.8		67.1			—		67.1
				1,301.60			—			1,301.60		1,301.90			—		1,301.90
	Acquisition-related Intangible Assets		$	19,147.00		$	-5,524.50		$	13,622.50	$	19,434.00		$	-5,323.90	$	14,110.10
Indefinite-lived Acquisition-related Intangible Assets [Table Text Block]	Acquisition-related Intangible Assets
	Acquisition-related intangible assets are as follows:
			28-Mar-15								31-Dec-14
					Accumulated								Accumulated
	(In millions)		Gross			Amortization			Net		Gross			Amortization		Net
	Definite Lived:
		Customer relationships	$	11,725.20		$	-3,510.10		$	8,215.10	$	11,866.80		$	-3,340.60	$	8,526.20
		Product technology		4,785.80			-1,515.20			3,270.60		4,898.10			-1,501.30		3,396.80
		Tradenames		1,300.90			-466.3			834.6		1,333.00			-448.7		884.3
		Other		33.5			-32.9			0.6		34.2			-33.3		0.9
				17,845.40			-5,524.50			12,320.90		18,132.10			-5,323.90		12,808.20
	Indefinite Lived:
		Tradenames		1,234.80			—			1,234.80		1,234.80			—		1,234.80
		In-process research and development		66.8			—			66.8		67.1			—		67.1
				1,301.60			—			1,301.60		1,301.90			—		1,301.90
	Acquisition-related Intangible Assets		$	19,147.00		$	-5,524.50		$	13,622.50	$	19,434.00		$	-5,323.90	$	14,110.10

Acquisitions_and_Dispositions_1

Acquisitions and Dispositions (Tables)	3 Months Ended
	Mar. 28, 2015
Acquisitions and Dispositions Disclosure
Schedule of Business Acquisitions, by Acquisition [Table Text Block]			The components of the purchase price and net assets acquired for 2015 acquisitions are as follows:
	(In millions)				Advanced Scientifics		Other		Total
	Purchase Price
		Cash paid			$	289.1	$	9.6	$	298.7
		Purchase price payable				—		1.3		1.3
		Cash acquired				-0.1		—		-0.1
					$	289	$	10.9	$	299.9
	Net Assets Acquired
		Current assets			$	27.9	$	3.9	$	31.8
		Property, plant and equipment				10.6		—		10.6
		Definite-lived intangible assets:
			Customer relationships			96.1		4.3		100.4
			Product technology			37.3		—		37.3
			Tradenames and other			2.3		—		2.3
		Goodwill				118.1		4.2		122.3
		Other assets				0.2		—		0.2
		Liabilities assumed				-3.5		-1.5		-5
					$	289	$	10.9	$	299.9
Business Acquisition, Pro Forma Information [Table Text Block]	Had the acquisition of Life Technologies been completed as of the beginning of 2013, the company’s pro forma results for the first three months of 2014 would have been as follows:
					Three Months Ended
				March 29,
	(In millions except per share amounts)				2014
	Revenues				$	4,176.40
	Net Income				$	728.5
	Earnings per Share:
		Basic			$	1.83
		Diluted			$	1.81

Business_Segment_Information_T

Business Segment Information (Tables)	3 Months Ended
	Mar. 28, 2015
Business Segments
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Business Segment Information
					Three Months Ended
				March 28,			March 29,
	(In millions)				2015			2014
	Revenues
		Life Sciences Solutions			$	1,019.90		$	835.5
		Analytical Instruments				727.4			769.9
		Specialty Diagnostics				785.2			813.7
		Laboratory Products and Services				1,513.40			1,590.50
		Eliminations				-127.1			-106.1
			Consolidated revenues			3,918.80			3,903.50
	Segment Income (a)
		Life Sciences Solutions				298.7			244.6
		Analytical Instruments				121.7			130.9
		Specialty Diagnostics				214.1			221
		Laboratory Products and Services				222.1			234
			Subtotal reportable segments (a)			856.6			830.5
		Cost of revenues charges				-0.6			-168.5
		Selling, general and administrative charges, net				-7.6			-82.8
		Restructuring and other (costs) income, net				-32			582.2
		Amortization of acquisition-related intangible assets				-329.1			-285.9
			Consolidated operating income			487.3			875.5
		Other expense, net (b)				-105.3			-101.1
		Income from continuing operations before income taxes			$	382		$	774.4
	Depreciation
		Life Sciences Solutions			$	33.5		$	24
		Analytical Instruments				9.3			10.4
		Specialty Diagnostics				17.8			18.8
		Laboratory Products and Services				26.6			26.5
			Consolidated depreciation		$	87.2		$	79.7
	(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.
	(b)	The company does not allocate other expense, net to its segments.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	Business Segment Information
					Three Months Ended
				March 28,			March 29,
	(In millions)				2015			2014
	Revenues
		Life Sciences Solutions			$	1,019.90		$	835.5
		Analytical Instruments				727.4			769.9
		Specialty Diagnostics				785.2			813.7
		Laboratory Products and Services				1,513.40			1,590.50
		Eliminations				-127.1			-106.1
			Consolidated revenues			3,918.80			3,903.50
	Segment Income (a)
		Life Sciences Solutions				298.7			244.6
		Analytical Instruments				121.7			130.9
		Specialty Diagnostics				214.1			221
		Laboratory Products and Services				222.1			234
			Subtotal reportable segments (a)			856.6			830.5
		Cost of revenues charges				-0.6			-168.5
		Selling, general and administrative charges, net				-7.6			-82.8
		Restructuring and other (costs) income, net				-32			582.2
		Amortization of acquisition-related intangible assets				-329.1			-285.9
			Consolidated operating income			487.3			875.5
		Other expense, net (b)				-105.3			-101.1
		Income from continuing operations before income taxes			$	382		$	774.4
	Depreciation
		Life Sciences Solutions			$	33.5		$	24
		Analytical Instruments				9.3			10.4
		Specialty Diagnostics				17.8			18.8
		Laboratory Products and Services				26.6			26.5
			Consolidated depreciation		$	87.2		$	79.7
	(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.
	(b)	The company does not allocate other expense, net to its segments.

Other_Expense_Net_Tables

Other Expense, Net (Tables)	3 Months Ended
	Mar. 28, 2015
Other Expense, Net Disclosure
Schedule of Other Nonoperating Income (Expense) [Table Text Block]			Three Months Ended
		March 28,			March 29,
	(In millions)		2015			2014
	Interest Income		$	7		$	11.9
	Interest Expense			-108.4			-117.8
	Other Items, Net			-3.9			4.8
	Other Expense, Net		$	-105.3		$	-101.1

Stockbased_Compensation_Expens1

Stockbased Compensation Expense (Tables)	3 Months Ended
	Mar. 28, 2015
Stock-based Compensation Expense Disclosure [Abstract]
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]		The components of stock-based compensation expense are primarily included in selling, general and
	administrative expenses and include the following:
				Three Months Ended
			March 28,			March 29,
	(In millions)			2015			2014
	Stock Option Awards			$	10.4		$	10.7
	Restricted Unit Awards				17.8			14.5
	Total Stock-based Compensation Expense			$	28.2		$	25.2

Pensions_and_Other_Postretirem

Pensions and Other Postretirement Benefit Plans (Tables)	3 Months Ended
	Mar. 28, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule of Net Benefit Costs [Table Text Block]		Net periodic benefit costs for the company’s defined benefit pension plans include the following components:
				Three Months Ended
			March 28,			March 29,
	(In millions)			2015			2014
	Service Cost-Benefits Earned			$	6.2		$	4.6
	Interest Cost on Benefit Obligation				19.4			20.1
	Expected Return on Plan Assets				-23.3			-21.1
	Amortization of Actuarial Net Loss				2.3			1.9
	Net Periodic Benefit Cost			$	4.6		$	5.5

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
	Mar. 28, 2015
Income Taxes Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]			The provision for income taxes in the accompanying statement of income differs from the provision calculated
	by applying the statutory federal income tax rate of 35% to income from continuing operations before provision for
	income taxes due to the following:
					Three Months Ended
				March 28,			March 29,
	(In millions)				2015			2014
	Provision for Income Taxes at Statutory Rate				$	133.7		$	271
	Increases (Decreases) Resulting From:
		Foreign rate differential				-23.8			-6.1
		Income tax credits				-103.1			-1.1
		Manufacturing deduction				-7.6			-0.6
		Singapore tax holiday				-3.2			-0.2
		Impact of change in tax laws and apportionment on deferred taxes				0.7			-20.5
		Nondeductible expenses				1.9			0.1
		Provision (reversal) of tax reserves, net				—			25.3
		Basis difference on disposal of businesses				—			-61.9
		State income taxes, net of federal tax				-1.6			23.3
		Other, net				-0.1			2
					$	-3.1		$	231.3

Earnings_per_Share_Tables

Earnings per Share (Tables)	3 Months Ended
	Mar. 28, 2015
Earnings per Share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]				Three Months Ended
			March 28,			March 29,
	(In millions except per share amounts)			2015			2014
	Net Income			$	385.1		$	543.1
	Basic Weighted Average Shares				397.8			393.3
	Plus Effect of:
		Equity forward arrangement			—			0.7
		Stock options and restricted units			3.6			4.4
	Diluted Weighted Average Shares				401.4			398.4
	Basic Earnings per Share			$	0.97		$	1.38
	Diluted Earnings per Share			$	0.96		$	1.36

Debt_and_Other_Financing_Arran1

Debt and Other Financing Arrangements (Tables)	3 Months Ended
	Mar. 28, 2015
Debt And Other Financing Arrangements Disclosure [Abstract]
Schedule of Debt [Table Text Block]			Effective
			Interest Rate at
			March 28,	March 28,			December 31,
	(Dollars in millions)		2015		2015		2014
	Commercial Paper		0.83%		$	1,220.70	$	—
	Term Loan		1.64%			1,175.00		1,275.00
	4.40% 5-Year Senior Notes, Due 3/1/2015					—		500
	3.20% 5-Year Senior Notes, Due 5/1/2015		1.55%			450		450
	5.00% 10-Year Senior Notes, Due 6/1/2015					—		250
	3.50% 5-Year Senior Notes, Due 1/15/2016		1.06%			400		400
	3.20% 5-Year Senior Notes, Due 3/1/2016		3.21%			900		900
	2.25% 5-Year Senior Notes, Due 8/15/2016		2.29%			1,000.00		1,000.00
	1.30% 3-Year Senior Notes, Due 2/1/2017		0.85%			900		900
	1.85% 5-Year Senior Notes, Due 1/15/2018		1.85%			500		500
	2.40% 5-Year Senior Notes, Due 2/1/2019		2.44%			900		900
	6.00% 10-Year Senior Notes, Due 3/1/2020		2.98%			750		750
	4.70% 10-Year Senior Notes, Due 5/1/2020		3.23%			300		300
	5.00% 10-Year Senior Notes, Due 1/15/2021		3.25%			400		400
	4.50% 10-Year Senior Notes, Due 3/1/2021		3.03%			1,000.00		1,000.00
	3.60% 10-Year Senior Notes, Due 8/15/2021		2.52%			1,100.00		1,100.00
	3.30% 7-Year Senior Notes, Due 2/15/2022		3.30%			800		800
	3.15% 10-Year Senior Notes, Due 1/15/2023		3.21%			800		800
	4.15% 10-Year Senior Notes, Due 2/1/2024		4.07%			1,000.00		1,000.00
	2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated)		2.03%			696.9		774.3
	5.30% 30-Year Senior Notes, Due 2/1/2044		5.30%			400		400
	Other					21.8		23.2
	Total Borrowings at Par Value					14,714.40		14,422.50
		Fair Value Hedge Accounting Adjustments				11.2		-0.5
		Unamortized Premium (Discount), Net				131.2		142
	Total Borrowings at Carrying Value					14,856.80		14,564.00
		Less: Short-term Obligations and Current Maturities				4,160.60		2,212.40
	Long-term Obligations				$	10,696.20	$	12,351.60

Comprehensive_Income_and_Share1

Comprehensive Income and Shareholders Equity (Tables)	3 Months Ended
	Mar. 28, 2015
Comprehensive Income and Shareholders Equity Disclosure [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]			Changes in each component of accumulated other comprehensive items, net of tax are as follows:
	(In millions)				Currency Translation Adjustment		Unrealized Gains (Losses) on Available-for-Sale Investments			Unrealized Gains (Losses) on Hedging Instruments			Pension and Other Postretirement Benefit Liability Adjustment		Total
	Balance at December 31, 2014				$	-1,070.60	$	1.3		$	-20.9		$	-194.8	$	-1,285.00
		Other comprehensive income (loss) before reclassifications				-563.1		0.1			-8			6.6		-564.4
		Amounts reclassified from accumulated other comprehensive items				—		—			1.1			1.7		2.8
			Net other comprehensive items			-563.1		0.1			-6.9			8.3		-561.6
	Balance at March 28, 2015				$	-1,633.70	$	1.4		$	-27.8		$	-186.5	$	-1,846.60
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]			The amounts reclassified out of accumulated other comprehensive items are as follows:
										Three Months Ended
						Affected Line Item in the			March 28,			March 29,
	(In millions)					Statement of Income				2015			2014
	Amounts Reclassified From Accumulated Other Comprehensive Items
		Unrealized gains and losses on hedging instruments:
			Realized loss on interest rate swaps and locks			Other Expense, Net				$	1.2		$	1.1
			Tax benefit			Provision for Income Taxes					-0.1			-0.4
											1.1			0.7
		Pension and other postretirement benefit liability adjustment:
			Amortization of actuarial losses			Net Periodic Benefit Cost -					2.4			1.9
						see Note 6 for details
				Total before tax							2.4			1.9
			Tax benefit			Provision for Income Taxes					-0.7			-0.6
											1.7			1.3
				Total reclassifications						$	2.8		$	2

Fair_Value_Measurements_and_Fa1

Fair Value Measurements and Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 28, 2015
Fair Value Measurements and Fair Value of Financial Instruments Disclosure
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]			The following table presents information about the company’s financial assets and liabilities measured at fair
	value on a recurring basis as of March 28, 2015:
				March 28,				Quoted Prices in Active Markets			Significant Other Observable Inputs		Significant Unobservable Inputs
	(In millions)				2015			(Level 1)			(Level 2)		(Level 3)
	Assets
		Cash equivalents			$	22.7		$	22.7		$	—	$	—
		Bank time deposits				8.4			8.4			—		—
		Investments in mutual funds, unit trusts and other    similar instruments				7.9			7.9			—		—
		Insurance contracts				102			—			102		—
		Derivative contracts				16.1			—			16.1		—
			Total Assets		$	157.1		$	39		$	118.1	$	—
	Liabilities
		Derivative contracts			$	26.3		$	—		$	26.3	$	—
		Contingent consideration				21			—			—		21
			Total Liabilities		$	47.3		$	—		$	26.3	$	21
			The following table presents information about the company’s financial assets and liabilities measured at fair
	value on a recurring basis as of December 31, 2014:
				December 31,				Quoted Prices in Active Markets			Significant Other Observable Inputs		Significant Unobservable Inputs
	(In millions)				2014			(Level 1)			(Level 2)		(Level 3)
	Assets
		Cash equivalents			$	617.3		$	617.3		$	—	$	—
		Bank time deposits				8.5			8.5			—		—
		Investments in mutual funds, unit trusts and other    similar instruments				8.7			8.7			—		—
		Insurance contracts				102.5			—			102.5		—
		Derivative contracts				20.2			—			20.2		—
			Total Assets		$	757.2		$	634.5		$	122.7	$	—
	Liabilities
		Derivative contracts			$	10.4		$	—		$	10.4	$	—
		Contingent consideration				29.6			—			—		29.6
			Total Liabilities		$	40		$	—		$	10.4	$	29.6
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a rollforward of the fair value, as determined by Level 3 inputs, of the contingent consideration.
				Three Months Ended
			March 28,			March 29,
	(In millions)			2015			2014
	Contingent Consideration
		Beginning Balance		$	29.6		$	5.1
		Acquisition			—			29.1
		Payments			-8			-1.1
		Change in fair value included in earnings			-0.5			—
		Currency translation			-0.1			—
		Ending Balance		$	21		$	33.1
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]					Fair Value – Assets						Fair Value – Liabilities
				March 28,				December 31,		March 28,			December 31,
	(In millions)				2015			2014			2015		2014
	Derivatives Designated as Hedging Instruments
		Interest rate swaps (a)			$	3.5		$	—		$	13.4	$	3.7
	Derivatives Not Designated as Hedging Instruments
		Currency exchange contracts (b)				12.6			20.2			12.9		6.7
	(a)		The fair value of the interest rate swaps is included in the consolidated balance sheet under the caption other long-term liabilities.
	(b)		The fair value of the currency exchange contracts is included in the consolidated balance sheet under the captions other current assets or other accrued expenses.
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]							Gain (Loss) Recognized
							Three Months Ended
							March 28,		March 29,
	(In millions)							2015			2014
	Derivatives Designated as Fair Value Hedges
		Interest rate swaps - effective portion					$	6.7		$	1.1
		Interest rate swaps - ineffective portion (a)						-7			0.7
	Derivatives Not Designated as Fair Value Hedges
		Currency exchange contracts
			Included in cost of revenues				$	13.4		$	0.8
			Included in other expense, net					119.9			0.7
	(a)		The ineffective portion of the loss recognized on interest rate swaps during the three months ended March 28, 2015 includes $7.5 million of costs associated with entering into the swap arrangements.
Fair Value, by Balance Sheet Grouping [Table Text Block]			The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:
					28-Mar-15						31-Dec-14
					Carrying			Fair			Carrying		Fair
	(In millions)				Value			Value			Value		Value
	Notes Receivable				$	8.8		$	8.8		$	8.3	$	8.3
	Debt Obligations:
		Senior notes			$	12,439.30		$	12,897.10		$	13,265.80	$	13,590.60
		Term loan				1,175.00			1,175.00			1,275.00		1,275.00
		Commercial paper				1,220.70			1,220.70			—		—
		Other				21.8			21.8			23.2		23.2
					$	14,856.80		$	15,314.60		$	14,564.00	$	14,888.80
			The fair value of debt obligations was determined based on quoted market prices and on borrowing rates
	available to the company at the respective period ends which represent level 2 measurements.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]			The carrying value and fair value of the company’s notes receivable and debt obligations are as follows:
					28-Mar-15						31-Dec-14
					Carrying			Fair			Carrying		Fair
	(In millions)				Value			Value			Value		Value
	Notes Receivable				$	8.8		$	8.8		$	8.3	$	8.3
	Debt Obligations:
		Senior notes			$	12,439.30		$	12,897.10		$	13,265.80	$	13,590.60
		Term loan				1,175.00			1,175.00			1,275.00		1,275.00
		Commercial paper				1,220.70			1,220.70			—		—
		Other				21.8			21.8			23.2		23.2
					$	14,856.80		$	15,314.60		$	14,564.00	$	14,888.80
			The fair value of debt obligations was determined based on quoted market prices and on borrowing rates
	available to the company at the respective period ends which represent level 2 measurements.

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 28, 2015
Supplemental Cash Flow Information [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]				Three Months Ended
			March 28,			March 29,
	(In millions)			2015			2014
	Non-cash Activities
		Fair value of assets of acquired businesses		$	305		$	19,640.10
		Cash paid for acquired businesses			-298.7			-13,528.90
		Liabilities assumed of acquired businesses		$	6.3		$	6,111.20
		Declared but unpaid dividends		$	61		$	61.1
		Issuance of stock upon vesting of restricted stock units		$	76.7		$	73.6

Restructuring_and_Other_Costs_1

Restructuring and Other Costs (Income), Net (Tables)	3 Months Ended
	Mar. 28, 2015
Restructuring And Other Costs, Net Disclosure
Schedule of Restructuring and Related Costs [Table Text Block]	First Three Months of 2015
	During the first three months of 2015, the company recorded net restructuring and other costs by segment as follows:
	(In millions)		Cost of Revenues			Selling, General and Administrative Expenses			Restructuring and Other Costs, Net			Total
	Life Sciences Solutions		$	0.5		$	6.1		$	22.7		$	29.3
	Analytical Instruments			—			—			5.6			5.6
	Specialty Diagnostics			0.1			—			2.8			2.9
	Laboratory Products and Services			—			-0.5			0.9			0.4
	Corporate			—			2			—			2
			$	0.6		$	7.6		$	32		$	40.2
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes the cash components of the company’s restructuring plans. The non-cash components and other amounts reported as restructuring and other costs, net, in the accompanying statement of income have been summarized in the notes to the tables. Accrued restructuring costs are included in other accrued expenses in the accompanying balance sheet.
							Abandonment
	(In millions)				Severance			of Excess Facilities			Other (a)			Total
	Pre-2014 Restructuring Plans
		Balance At December 31, 2014			$	6.2		$	7.5		$	1.8		$	15.5
		Costs incurred in 2015 (b)				0.3			0.2			0.1			0.6
		Reserves reversed				—			—			—			—
		Payments				-1.7			-0.8			-0.5			-3
		Currency translation				-0.3			-0.2			-0.2			-0.7
		Balance At March 28, 2015			$	4.5		$	6.7		$	1.2		$	12.4
	2014 Restructuring Plans
		Balance At December 31, 2014			$	31.5		$	2.3		$	4.1		$	37.9
		Costs incurred in 2015 (b)				4.4			0.7			3.3			8.4
		Reserves reversed				-4.6			—			-1.1			-5.7
		Payments				-20.6			-2.4			-4			-27
		Currency translation				-0.7			—			-0.1			-0.8
		Balance At March 28, 2015			$	10		$	0.6		$	2.2		$	12.8
	2015 Restructuring Plans
		Costs incurred in 2015 (b)			$	21.6		$	0.1		$	0.9		$	22.6
		Payments				-11.1			-0.1			-0.4			-11.6
		Currency translation				0.3			—			—			0.3
		Balance At March 28, 2015			$	10.8		$	—		$	0.5		$	11.3
	Other includes cash charges for relocation and moving expenses associated with facility consolidations, as well as employee retention costs which are accrued ratably over the period through which employees must work to qualify for a payment.
	Excludes $5.0 million of cash compensation contractually due to employees of an acquired business on the date of acquisition; $0.9 million of charges associated with a previous sale of a business; and an aggregate of $0.2 million of non-cash charges, net, which are detailed by segment above.
	The company expects to pay accrued restructuring costs as follows: severance, employee-retention obligations and other costs primarily through 2015 and abandoned-facility payments, over lease terms expiring through 2020.

Warranty_Obligations_Details

Warranty Obligations (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Warranty Obligation [Roll Forward]
Beginning Balance	$57.50	$49.80
Provision charged to income	17.2	19
Usage	-18.3	-18.4
Acquisitions	0.5	7.2
Adjustments to previously provided warranties, net	-0.1	0.6
Currency translation	-1.9	-0.4
Ending Balance	$54.90	$57.80

Inventories_Details

Inventories (Details) (USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Inventories [Abstract]
Raw Materials	$459.60	$441.60
Work in Process	220.7	207.6
Finished Goods	1,218.50	1,210.30
Inventories	$1,898.80	$1,859.50

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	$3,868.90		$3,868.90
Less: Accumulated depreciation and amortization	1,484.70		1,442.40
Property, Plant and Equipment, at Cost, Net	2,384.20		2,426.50
Depreciation and amortization expense of property, plant and equipment	87.2	79.7
Land [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	280.2		281.8
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	955.6		955.1
Machinery, Equipment and Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, at Cost	$2,633.10		$2,632

Acquisitionrelated_Intangible_

Acquisition-related Intangible Assets (Details) (USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	$17,845.40	$18,132.10
Accumulated Amortization	-5,524.50	-5,323.90
Definite-Lived Intangible Assets, Net	12,320.90	12,808.20
Indefinite-lived Intangible Assets by Major Class [Line Items]
Indefinite-Lived Intangible Assets	1,301.60	1,301.90
Acquisition-related Intangible Assets, Gross	19,147	19,434
Acquisition-related Intangible Assets, net of Accumulated Amortization	13,622.50	14,110.10
Tradenames [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]
Indefinite-Lived Intangible Assets	1,234.80	1,234.80
In-process Research and Development [Member]
Indefinite-lived Intangible Assets by Major Class [Line Items]
Indefinite-Lived Intangible Assets	66.8	67.1
Customer Relationships [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	11,725.20	11,866.80
Accumulated Amortization	-3,510.10	-3,340.60
Definite-Lived Intangible Assets, Net	8,215.10	8,526.20
Product Technology [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	4,785.80	4,898.10
Accumulated Amortization	-1,515.20	-1,501.30
Definite-Lived Intangible Assets, Net	3,270.60	3,396.80
Tradenames [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	1,300.90	1,333
Accumulated Amortization	-466.3	-448.7
Definite-Lived Intangible Assets, Net	834.6	884.3
Other Intangible Assets [Member]
Definite-Lived Intangible Assets [Line Items]
Definite-Lived Intangible Assets, Gross	33.5	34.2
Accumulated Amortization	-32.9	-33.3
Definite-Lived Intangible Assets, Net	$0.60	$0.90

Completed_Acquisitions_Purchas

Completed Acquisitions Purchase Price (Details) (USD $)	3 Months Ended		1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014	Feb. 28, 2015	Dec. 31, 2014
Purchase Price
Cash Paid	$298.70	$13,528.90
Purchase Price Payable	1.3
Cash acquired	-0.1
Total Purchase Price	299.9
Net Assets Acquired
Current assets	31.8
Property, plant and equipment	10.6
Goodwill	122.3
Other assets	0.2
Liabilities assumed	-5
Total Purchase Price	299.9
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life (in years)	15 years
Other Information
Purchase Price Paid	298.6	13,056.30
Purchase Price Paid For Acquisitions Completed In A Prior Year	8
Customer Relationships [Member]
Net Assets Acquired
Definite-lived intangible assets	100.4
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life (in years)	16 years
Product Technology [Member]
Net Assets Acquired
Definite-lived intangible assets	37.3
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life (in years)	11 years
Tradenames and other [Member]
Net Assets Acquired
Definite-lived intangible assets	2.3
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life (in years)	10 years
Advanced Scientifics, Inc. [Member]
Purchase Price
Cash Paid			289.1
Cash acquired			-0.1
Total Purchase Price			289
Net Assets Acquired
Current assets			27.9
Property, plant and equipment			10.6
Goodwill			118.1
Other assets			0.2
Liabilities assumed			-3.5
Total Purchase Price			289
Other Information
Revenue Reported by Acquired Entity				80
Goodwill, Expected Tax Deductible Amount			118.1
Advanced Scientifics, Inc. [Member] | Customer Relationships [Member]
Net Assets Acquired
Definite-lived intangible assets			96.1
Advanced Scientifics, Inc. [Member] | Product Technology [Member]
Net Assets Acquired
Definite-lived intangible assets			37.3
Advanced Scientifics, Inc. [Member] | Tradenames and other [Member]
Net Assets Acquired
Definite-lived intangible assets			2.3
Other Acquisitions [Member]
Purchase Price
Cash Paid	9.6
Purchase Price Payable	1.3
Total Purchase Price	10.9
Net Assets Acquired
Current assets	3.9
Goodwill	4.2
Liabilities assumed	-1.5
Total Purchase Price	10.9
Other Acquisitions [Member] | Customer Relationships [Member]
Net Assets Acquired
Definite-lived intangible assets	$4.30

Acquisition_Pro_Forma_Results_

Acquisition Pro Forma Results (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 29, 2014
Business Acquisition, Pro Forma Information [Abstract]
Revenues	$4,176.40
Net Income	$728.50
Earnings per Share:
Basic (in dollars per share)	$1.83
Diluted (in dollars per share)	$1.81

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015		Mar. 29, 2014		Dec. 31, 2014
	Segment
Business Segments
Number of Reportable Segments	4
Segment Reporting Information [Line Items]
Revenues	$3,918.80		$3,903.50
Cost of revenues charges	-0.6
Selling, general and administrative charges, net	-7.6
Restructuring and other income (costs), net	-32		582.2
Operating Income	487.3		875.5
Other expense, net	-105.3		-101.1
Income from Continuing Operations Before Income Taxes	382		774.4
Depreciation	87.2		79.7
Total Assets	41,857.30				42,852.10
Capital Expenditures	97.2		104.7
Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges	-0.5
Selling, general and administrative charges, net	-6.1
Restructuring and other income (costs), net	-22.7
Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges	0
Selling, general and administrative charges, net	0
Restructuring and other income (costs), net	-5.6
Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges	-0.1
Selling, general and administrative charges, net	0
Restructuring and other income (costs), net	-2.8
Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges	0
Selling, general and administrative charges, net	0.5
Restructuring and other income (costs), net	-0.9
Total Reportable Segments [Member]
Segment Reporting Information [Line Items]
Operating Income	856.6	[1]	830.5	[1]
Total Reportable Segments [Member] | Life Sciences Solutions [Member]
Segment Reporting Information [Line Items]
Revenues	1,019.90		835.5
Operating Income	298.7	[1]	244.6	[1]
Depreciation	33.5		24
Total Reportable Segments [Member] | Analytical Instruments [Member]
Segment Reporting Information [Line Items]
Revenues	727.4		769.9
Operating Income	121.7	[1]	130.9	[1]
Depreciation	9.3		10.4
Total Reportable Segments [Member] | Specialty Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenues	785.2		813.7
Operating Income	214.1	[1]	221	[1]
Depreciation	17.8		18.8
Total Reportable Segments [Member] | Laboratory Products and Services [Member]
Segment Reporting Information [Line Items]
Revenues	1,513.40		1,590.50
Operating Income	222.1	[1]	234	[1]
Depreciation	26.6		26.5
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues	-127.1		-106.1
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost of revenues charges	-0.6		-168.5
Selling, general and administrative charges, net	-7.6		-82.8
Restructuring and other income (costs), net	-32		582.2
Amortization of acquisition-related intangible assets	($329.10)		($285.90)
[1]	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.

Other_Expense_Net_Details

Other Expense, Net (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Other Expense, Net Disclosure
Interest Income	$7	$11.90
Interest Expense	-108.4	-117.8
Other Items, Net	-3.9	4.8
Other Expense, Net	-105.3	-101.1
Gain on sale of investment accounted for under cost method		4
Losses on Extinguishment of Debt	3
Costs associated with entering into interest rate swap arrangements	$7.50

Stockbased_Compensation_Expens2

Stockbased Compensation Expense (Details) (USD $)	3 Months Ended
	Mar. 28, 2015	Mar. 29, 2014
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Stock Option Awards	$10,400,000	$10,700,000
Restricted Unit Awards	17,800,000	14,500,000
Stock-based Compensation Expense	28,200,000	25,200,000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation Expense, Cash-in-Lieu of Pre-acquisition Equity Awards	8,400,000	7,100,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Costs On Nonvested Awards	111,000,000
Unrecognized Compensation Costs On Nonvested Awards, Weighted Average Period Of Recognition	2 years 9 months
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Costs On Nonvested Awards, Period Of Recognition	4 years
Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Costs On Nonvested Awards	$181,000,000
Unrecognized Compensation Costs On Nonvested Awards, Weighted Average Period Of Recognition	2 years 7 months
Restricted Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Compensation Costs On Nonvested Awards, Period Of Recognition	3 years

Stockbased_Compensation_Stock_

Stockbased Compensation, Stock Option Disclosures (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Stock-based Compensation Expense Disclosure [Abstract]
Tax benefit related to employees' and directors' stock plans	$39	$48.20
Options Outstanding [Roll Forward]
Granted	1.7

Stockbased_Compensation_Restri

Stockbased Compensation, Restricted Units Disclosures (Details)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015
Unvested Restricted Units [Roll Forward]
Granted	0.9

Pensions_Net_Benefit_Cost_Deta

Pensions Net Benefit Cost (Details) (Pension Plans, Defined Benefit [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Pension Plans, Defined Benefit [Member]
Components of Net Benefit Cost (Income)
Service Cost-Benefits Earned	$6.20	$4.60
Interest Cost on Benefit Obligation	19.4	20.1
Expected Return on Plan Assets	-23.3	-21.1
Amortization of Actuarial Net Loss	2.3	1.9
Net Periodic Benefit Cost	$4.60	$5.50

Income_Taxes_Rate_Reconciliati

Income Taxes Rate Reconciliation (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
Federal Statutory Income Tax Rate	35.00%	35.00%
Provision for Income Taxes at Statutory Rate	$133.70	$271
Foreign rate differential	-23.8	-6.1
Income tax credits	-103.1	-1.1
Manufacturing deduction	-7.6	-0.6
Singapore tax holiday	-3.2	-0.2
Impact of change in tax laws and apportionment on deferred taxes	0.7	-20.5
Nondeductible expenses	1.9	0.1
Provision (reversal) of tax reserves, net	0	25.3
Basis difference on disposal of businesses	0	-61.9
State income taxes, net of federal tax	-1.6	23.3
Other, net	-0.1	2
Provision for Income Taxes	-3.1	231.3
US foreign tax credits generated by repatriation of foreign earnings	77
US Income taxes on repatriated foreign earnings	$27

EPS_Calculation_Details

EPS Calculation (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Earnings per Share
Net Income	$385.10	$543.10
Basic Weighted Average Shares	397.8	393.3
Effect of Equity Forward Arrangement	0	0.7
Effect of Stock Options and Restricted Units	3.6	4.4
Diluted Weighted Average Shares	401.4	398.4
Basic Earnings per Share:
Earnings Per Share, Basic (in dollars per share)	$0.97	$1.38
Diluted Earnings per Share:
Earnings Per Share, Diluted (in dollars per share)	$0.96	$1.36
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Stock Options Excluded From Computation Of Earnings Per Share	4	2.4

Debt_Outstanding_Debt_Details

Debt Outstanding Debt (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Principal Outstanding	$14,714.40	$14,422.50
Fair Value Hedge Accounting Adjustments	11.2	-0.5
Unamortized Premium (Discount), Net	131.2	142
Debt Obligations - Carrying Value	14,856.80	14,564
Less: Short-term obligations and current maturities of long-term obligations	4,160.60	2,212.40
Long-term Obligations	10,696.20	12,351.60
Losses on Extinguishment of Debt	3
Commercial Paper [Member]
Debt Instrument [Line Items]
Effective Interest Rate	0.83%
Principal Outstanding	1,220.70	0
Debt Obligations - Carrying Value	1,220.70	0
Term Loan
Debt Instrument [Line Items]
Debt Instrument, Maturity Date	31-Mar-16
Effective Interest Rate	1.64%
Principal Outstanding	1,175	1,275
Debt Obligations - Carrying Value	1,175	1,275
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA	4
Debt, Covenant, Maximum Consolidated Total Leverage Ratio Of Debt To EBITDA by August 2015	3.5
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3
Senior Notes [Member]
Debt Instrument [Line Items]
Debt Obligations - Carrying Value	12,439.30	13,265.80
Debt Instrument, Call Feature	Each of the notes may be redeemed at any time at a redemption price of 100% of the principal amount plus a specified make-whole premium plus accrued interest
Senior Notes [Member] | 4.40% 5-Year Senior Notes, Due 3/1/2015 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.40%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	1-Mar-15
Principal Outstanding	0	500
Senior Notes [Member] | 3.20% 5-Year Senior Notes, Due 5/1/2015 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.20%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	1-May-15
Effective Interest Rate	1.55%
Principal Outstanding	450	450
Senior Notes [Member] | 5.00% 10-Year Senior Notes, Due 6/1/2015 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	1-Jun-15
Principal Outstanding	0	250
Losses on Extinguishment of Debt	3
Senior Notes [Member] | 3.50% 5-Year Senior Notes, Due 1/15/2016 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.50%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	15-Jan-16
Effective Interest Rate	1.06%
Principal Outstanding	400	400
Senior Notes [Member] | 3.20% 5-Year Senior Notes, Due 3/1/2016 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.20%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	1-Mar-16
Effective Interest Rate	3.21%
Principal Outstanding	900	900
Senior Notes [Member] | 2.25% 5-Year Senior Notes, Due 8/15/2016 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.25%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	15-Aug-16
Effective Interest Rate	2.29%
Principal Outstanding	1,000	1,000
Senior Notes [Member] | 1.30% 3-Year Senior Notes, Due 2/1/2017 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.30%
Debt Instrument, Term	3 years
Debt Instrument, Maturity Date	1-Feb-17
Effective Interest Rate	0.85%
Principal Outstanding	900	900
Senior Notes [Member] | 1.85% 5-Year Senior Notes, Due 1/15/2018 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	1.85%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	15-Jan-18
Effective Interest Rate	1.85%
Principal Outstanding	500	500
Senior Notes [Member] | 2.40% 5-Year Senior Notes, Due 2/1/2019 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.40%
Debt Instrument, Term	5 years
Debt Instrument, Maturity Date	1-Feb-19
Effective Interest Rate	2.44%
Principal Outstanding	900	900
Senior Notes [Member] | 6.00% 10-Year Senior Notes, Due 3/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	6.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	1-Mar-20
Effective Interest Rate	2.98%
Principal Outstanding	750	750
Senior Notes [Member] | 4.70% 10-Year Senior Notes, Due 5/1/2020 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.70%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	1-May-20
Effective Interest Rate	3.23%
Principal Outstanding	300	300
Senior Notes [Member] | 5.00% 10-Year Senior Notes, Due 1/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	15-Jan-21
Effective Interest Rate	3.25%
Principal Outstanding	400	400
Senior Notes [Member] | 4.50% 10-Year Senior Notes, Due 3/1/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.50%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	1-Mar-21
Effective Interest Rate	3.03%
Principal Outstanding	1,000	1,000
Senior Notes [Member] | 3.60% 10-Year Senior Notes, Due 8/15/2021 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.60%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	15-Aug-21
Effective Interest Rate	2.52%
Principal Outstanding	1,100	1,100
Senior Notes [Member] | 3.30% 7-Year Senior Notes, Due 2/15/2022 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.30%
Debt Instrument, Term	7 years
Debt Instrument, Maturity Date	15-Feb-22
Effective Interest Rate	3.30%
Principal Outstanding	800	800
Senior Notes [Member] | 3.15% 10-Year Senior Notes, Due 1/15/2023 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	3.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	15-Jan-23
Effective Interest Rate	3.21%
Principal Outstanding	800	800
Senior Notes [Member] | 4.15% 10-Year Senior Notes, Due 2/1/2024 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	4.15%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	1-Feb-24
Effective Interest Rate	4.07%
Principal Outstanding	1,000	1,000
Senior Notes [Member] | 2.00% 10-Year Senior Notes, Due 4/15/2025 (euro denominated) [Member]
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Debt Instrument, Term	10 years
Debt Instrument, Maturity Date	15-Apr-25
Effective Interest Rate	2.03%
Principal Outstanding	696.9	774.3
Senior Notes [Member] | 5.30% 30-Year Senior Notes, Due 2/1/2044 [Member]
Debt Instrument [Line Items]
Stated Interest Rate	5.30%
Debt Instrument, Term	30 years
Debt Instrument, Maturity Date	1-Feb-44
Effective Interest Rate	5.30%
Principal Outstanding	400	400
Other Debt [Member]
Debt Instrument [Line Items]
Principal Outstanding	21.8	23.2
Debt Obligations - Carrying Value	$21.80	$23.20

Debt_Future_Repayments_Details

Debt Future Repayments (Details) (USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Maturities of Long-term Debt [Abstract]
Total Repayments of Principal	$14,714.40	$14,422.50

Debt_Shortterm_Financing_Detai

Debt Short-term Financing (Details) (USD $)	3 Months Ended
	Mar. 28, 2015
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$2,000,000,000
Line of Credit Facility, Expiration Date	31-Jul-18
Debt, Covenant, Maximum Consolidated Total Leverage Ratio of Debt to EBITDA	4
Debt, Covenant, Maximum Consolidated Total Leverage Ratio Of Debt To EBITDA by August 2015	3.5
Debt, Covenant, Minimum Consolidated Interest Coverage Ratio	3
Letters of Credit Outstanding, Amount	59,000,000
Line of Credit Facility, Amount Outstanding	$0
U.S. Commercial Paper Program [Member]
Short-term Financing [Line Items]
Maximum Period to Maturity Allowed Under Program	397 days
Short-term Debt, Period to Maturity	46 days

Interest_Rate_Swap_Arrangement

Interest Rate Swap Arrangements (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014	Dec. 31, 2014
Debt Instrument [Line Items]
Notional Amount Of Derivatives	$6,250		$3,740
Change in fair value of cash flow hedges, net of tax	-8	0
Senior Notes 1.30% Due 2017 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	900
Interest Rate Swap, Spread above One-month LIBOR	0.66%
Interest Rate Swap, Variable Rate at Period End	0.83%
Fixed Interest Rate	1.30%
Senior Notes 4.70% Due 2020 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	300
Interest Rate Swap, Spread above One-month LIBOR	3.16%
Interest Rate Swap, Variable Rate at Period End	3.33%
Fixed Interest Rate	4.70%
Senior Notes 4.50% Due 2021 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	1,000
Interest Rate Swap, Spread above One-month LIBOR	2.87%
Interest Rate Swap, Variable Rate at Period End	3.04%
Fixed Interest Rate	4.50%
Senior Notes 3.60% Due 2021 [Member] | Interest Rate Swaps [Member]
Debt Instrument [Line Items]
Notional Amount Of Derivatives	$1,100
Interest Rate Swap, Spread above One-month LIBOR	1.94%
Interest Rate Swap, Variable Rate at Period End	2.11%
Fixed Interest Rate	3.60%

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Feb. 03, 2014	Mar. 28, 2015	Dec. 31, 2014
Accrual for Environmental Loss Contingencies Disclosure [Abstract]
Accrual for Environmental Loss Contingencies, Net		$31	$32
Enzo Biochem, Enzo Life Sciences and Yale Univ [Member]
Loss Contingency [Abstract]
Loss Contingency Accrued		60.9
Enzo Biochem, Enzo Life Sciences and Yale Univ [Member] | Life Technologies Corporation [Member]
Loss Contingency [Abstract]
Damages Awarded	48.5
Prejudgment Interest Awarded	12.4
Loss Contingency Accrued	60.9
Promega Corp and Max-Plank-Gesellschaft [Member] | Life Technologies Corporation [Member]
Loss Contingency [Abstract]
Damages Awarded	52
Loss Contingency Accrued	$52

Comprehensive_Income_and_Share2

Comprehensive Income and Shareholders' Equity (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Items, Beginning Balance	($1,285)
Other comprehensive income (loss) before reclassifications	-564.4
Amounts reclassified from accumulated other comprehensive items	2.8
Total other comprehensive items	-561.6	14.4
Accumulated Other Comprehensive Items, Ending Balance	-1,846.60
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other Expense, Net	105.3	101.1
Total Before Tax	-382	-774.4
Income Tax Provision (Benefit)	-3.1	231.3
Net of Tax	-385.1	-543.1
Class of Stock Disclosures [Abstract]
Preferred Stock, $100 Par Value - Shares Authorized (in shares)	50,000		50,000
Preferred Stock, $100 Par Value - Par Value (in dollars per share)	$100		$100
Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net of Tax	2.8	2
Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Items, Beginning Balance	-1,070.60
Other comprehensive income (loss) before reclassifications	-563.1
Total other comprehensive items	-563.1
Accumulated Other Comprehensive Items, Ending Balance	-1,633.70
Unrealized Gains (Losses) on Available-for-Sale Investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Items, Beginning Balance	1.3
Other comprehensive income (loss) before reclassifications	0.1
Amounts reclassified from accumulated other comprehensive items	0
Total other comprehensive items	0.1
Accumulated Other Comprehensive Items, Ending Balance	1.4
Unrealized Gains (Losses) on Hedging Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Items, Beginning Balance	-20.9
Other comprehensive income (loss) before reclassifications	-8
Amounts reclassified from accumulated other comprehensive items	1.1
Total other comprehensive items	-6.9
Accumulated Other Comprehensive Items, Ending Balance	-27.8
Unrealized Gains (Losses) on Hedging Instruments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other Expense, Net	1.2	1.1
Income Tax Provision (Benefit)	-0.1	-0.4
Net of Tax	1.1	0.7
Pension and Other Postretirement Benefit Liability Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Items, Beginning Balance	-194.8
Other comprehensive income (loss) before reclassifications	6.6
Amounts reclassified from accumulated other comprehensive items	1.7
Total other comprehensive items	8.3
Accumulated Other Comprehensive Items, Ending Balance	-186.5
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net Periodic Benefit Cost - Amortization of Actuarial Losses	2.4	1.9
Pension and Other Postretirement Benefit Liability Adjustment [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total Before Tax	2.4	1.9
Income Tax Provision (Benefit)	-0.7	-0.6
Net of Tax	$1.70	$1.30

Fair_Value_Measurements_Assets

Fair Value Measurements, Assets and Liabilities (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Assets
Cash equivalents	$22.70	$617.30
Bank time deposits	8.4	8.5
Investments in mutual funds, unit trusts and other similar instruments	7.9	8.7
Insurance contracts	102	102.5
Derivative contracts	16.1	20.2
Total Assets	157.1	757.2
Liabilities
Derivative contracts	26.3	10.4
Contingent consideration	21	29.6
Total Liabilities	47.3	40
Quoted Prices in Active Markets (Level I) [Member]
Assets
Cash equivalents	22.7	617.3
Bank time deposits	8.4	8.5
Investments in mutual funds, unit trusts and other similar instruments	7.9	8.7
Total Assets	39	634.5
Significant Other Observable Inputs (Level 2) [Member]
Assets
Insurance contracts	102	102.5
Derivative contracts	16.1	20.2
Total Assets	118.1	122.7
Liabilities
Derivative contracts	26.3	10.4
Total Liabilities	26.3	10.4
Significant Unobservable Inputs (Level 3) [Member]
Liabilities
Contingent consideration	21	29.6
Total Liabilities	$21	$29.60

Fair_Value_Measurements_Level_

Fair Value Measurements, Level 3 Reconciliation (Details) (Contingent Consideration [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$29.60	$5.10
Acquisition	0	29.1
Payments	-8	-1.1
Change in fair value included in earnings	-0.5	0
Currency translation	-0.1	0
Ending Balance	$21	$33.10

Fair_Value_Measurements_Deriva

Fair Value Measurements, Derivative Instruments (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015		Mar. 29, 2014	Dec. 31, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Costs associated with entering into interest rate swap arrangements included in ineffective portion of loss recognized	$7.50
Cash Flow Hedge Arrangements
Notional Amount Of Derivatives	6,250			3,740
Change in fair value of cash flow hedges, net of tax	-8		0
Net Investment Hedge
Gain (Loss) in Currency Translation Adjustment on Net Investment Hedge	77.1
Derivatives Designated as Cash Flow Hedges [Member]
Cash Flow Hedge Arrangements
Debt Instrument, Term	10 years
Notional Amount Of Derivatives	1,000
Change in fair value of cash flow hedges, net of tax	-8
Interest Rate Swaps [Member] | Other Expense [Member] | Derivatives Designated as Fair Value Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized	6.7		1.1
Ineffective Portion of Gain (Loss) Recognized	-7	[1]	0.7
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instruments | Other Assets [Member]
Fair Value - Assets
Derivative Asset, Fair Value	3.5
Interest Rate Swaps [Member] | Derivatives Designated as Hedging Instruments | Other Long-term Liabilities [Member]
Fair Value - Liabilities
Derivative Liability, Fair Value	13.4			3.7
Foreign Currency Exchange Contracts [Member] | Cost of Revenues [Member] | Derivatives Not Designated as Fair Value Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized	13.4		0.8
Foreign Currency Exchange Contracts [Member] | Other Expense [Member] | Derivatives Not Designated as Fair Value Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized	119.9		0.7
Foreign Currency Exchange Contracts [Member] | Derivatives Not Designated as Fair Value Hedges | Other Current Assets [Member]
Fair Value - Assets
Derivative Asset, Fair Value	12.6			20.2
Foreign Currency Exchange Contracts [Member] | Derivatives Not Designated as Fair Value Hedges | Accrued Expense [Member]
Fair Value - Liabilities
Derivative Liability, Fair Value	$12.90			$6.70
[1]	The ineffective portion of the loss recognized on interest rate swaps during the three months ended March 28, 2015 includes $7.5 million of costs associated with entering into the swap arrangements.

Fair_Value_of_Other_Instrument

Fair Value of Other Instruments (Details) (USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Other Financial Instruments [Abstract]
Notes Receivable - Carrying Value	$8.80	$8.30
Notes Receivable - Fair Value	8.8	8.3
Carrying Value and Fair Value of Other Financial Instruments [Line Items]
Debt Obligations - Carrying Value	14,856.80	14,564
Debt Obligations - Fair Value	15,314.60	14,888.80
Senior Notes [Member]
Carrying Value and Fair Value of Other Financial Instruments [Line Items]
Debt Obligations - Carrying Value	12,439.30	13,265.80
Debt Obligations - Fair Value	12,897.10	13,590.60
Term Loan
Carrying Value and Fair Value of Other Financial Instruments [Line Items]
Debt Obligations - Carrying Value	1,175	1,275
Debt Obligations - Fair Value	1,175	1,275
U.S. Commercial Paper Program [Member]
Carrying Value and Fair Value of Other Financial Instruments [Line Items]
Debt Obligations - Carrying Value	1,220.70	0
Debt Obligations - Fair Value	1,220.70	0
Other Debt [Member]
Carrying Value and Fair Value of Other Financial Instruments [Line Items]
Debt Obligations - Carrying Value	21.8	23.2
Debt Obligations - Fair Value	$21.80	$23.20

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Non-cash Activities [Abstract]
Fair value of assets of acquired businesses	$305	$19,640.10
Cash paid for acquired businesses	-298.7	-13,528.90
Liabilities assumed of acquired businesses	6.3	6,111.20
Declared but unpaid dividends	61	61.1
Issuance of stock upon vesting of restricted stock units	$76.70	$73.60

Restructuring_and_Other_Costs_2

Restructuring and Other Costs (Income), Net (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014	1-May-15
Restructuring And Other Costs, Net Disclosure
Restructuring and Related Cost, Percentage of Total Workforce Eliminated	1.00%
Identified Future Restructuring Costs			$70
Restructuring Reserve [Line Items]
Cost of Revenues	0.6
Selling, General and Administrative Expenses	7.6
Restructuring and Other Costs (Income), Net	32	-582.2
Total Restructuring and Other Costs (Income), Net	40.2
Restructuring and Related Costs, Non-Cash Costs (Income), Net	0.2
Gain (Loss) on Divestiture of Businesses	0	758.5
Transaction Costs Related to Divestiture [Member]
Restructuring Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	0.9
Charges for Cash Compensation Contractually Due to Employees of Acquired Business [Member]
Restructuring Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	5
Life Sciences Solutions [Member]
Restructuring Reserve [Line Items]
Cost of Revenues	0.5
Selling, General and Administrative Expenses	6.1
Restructuring and Other Costs (Income), Net	22.7
Total Restructuring and Other Costs (Income), Net	29.3
Restructuring and Related Costs, Cash Costs	22.5
Restructuring and Related Costs, Non-Cash Costs (Income), Net	0.2
Life Sciences Solutions [Member] | Costs associated with headcount reductions and facility consolidations
Restructuring Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	16.6
Life Sciences Solutions [Member] | Severance [Member]
Restructuring Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	14.7
Life Sciences Solutions [Member] | Abandonment of Excess Facilities [Member]
Restructuring Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	0.7
Life Sciences Solutions [Member] | Other Restructuring [Member]
Restructuring Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	1.2
Life Sciences Solutions [Member] | Transaction Costs Related to Divestiture [Member]
Restructuring Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	0.9
Life Sciences Solutions [Member] | Charges for Cash Compensation Contractually Due to Employees of Acquired Business [Member]
Restructuring Reserve [Line Items]
Restructuring and Related Costs, Cash Costs	5
Analytical Instruments [Member]
Restructuring Reserve [Line Items]
Cost of Revenues	0
Selling, General and Administrative Expenses	0
Restructuring and Other Costs (Income), Net	5.6
Total Restructuring and Other Costs (Income), Net	5.6
Restructuring and Related Costs, Cash Costs	5.6
Specialty Diagnostics [Member]
Restructuring Reserve [Line Items]
Cost of Revenues	0.1
Selling, General and Administrative Expenses	0
Restructuring and Other Costs (Income), Net	2.8
Total Restructuring and Other Costs (Income), Net	2.9
Restructuring and Related Costs, Cash Costs	2.8
Laboratory Products and Services [Member]
Restructuring Reserve [Line Items]
Cost of Revenues	0
Selling, General and Administrative Expenses	-0.5
Restructuring and Other Costs (Income), Net	0.9
Total Restructuring and Other Costs (Income), Net	0.4
Laboratory Products and Services [Member] | Charges for Changes in Estimates of Contingent Consideration for Acquisitions [Member]
Restructuring Reserve [Line Items]
Selling, General and Administrative Expenses	-0.5
Corporate [Member]
Restructuring Reserve [Line Items]
Cost of Revenues	0
Selling, General and Administrative Expenses	2
Restructuring and Other Costs (Income), Net	0
Total Restructuring and Other Costs (Income), Net	$2

Restructuring_Reserves_Details

Restructuring Reserves (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015
Severance [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Expected Final Year of Payments	2015
Abandonment of Excess Facilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Expected Final Year of Payments	2020
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Expected Final Year of Payments	2015
Pre-2014 Restructuring Plans [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	15.5
Costs incurred	0.6
Reserves reversed	0
Payments	-3
Currency translation	-0.7
Ending balance	12.4
Pre-2014 Restructuring Plans [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	6.2
Costs incurred	0.3
Reserves reversed	0
Payments	-1.7
Currency translation	-0.3
Ending balance	4.5
Pre-2014 Restructuring Plans [Member] | Abandonment of Excess Facilities [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	7.5
Costs incurred	0.2
Reserves reversed	0
Payments	-0.8
Currency translation	-0.2
Ending balance	6.7
Pre-2014 Restructuring Plans [Member] | Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	1.8
Costs incurred	0.1
Reserves reversed	0
Payments	-0.5
Currency translation	-0.2
Ending balance	1.2
2014 Restructuring Plans [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	37.9
Costs incurred	8.4
Reserves reversed	-5.7
Payments	-27
Currency translation	-0.8
Ending balance	12.8
2014 Restructuring Plans [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	31.5
Costs incurred	4.4
Reserves reversed	-4.6
Payments	-20.6
Currency translation	-0.7
Ending balance	10
2014 Restructuring Plans [Member] | Abandonment of Excess Facilities [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	2.3
Costs incurred	0.7
Reserves reversed	0
Payments	-2.4
Currency translation	0
Ending balance	0.6
2014 Restructuring Plans [Member] | Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Beginning balance	4.1
Costs incurred	3.3
Reserves reversed	-1.1
Payments	-4
Currency translation	-0.1
Ending balance	2.2
2015 Restructuring Plans [Member]
Restructuring Reserve [Roll Forward]
Costs incurred	22.6
Payments	-11.6
Currency translation	0.3
Ending balance	11.3
2015 Restructuring Plans [Member] | Severance [Member]
Restructuring Reserve [Roll Forward]
Costs incurred	21.6
Payments	-11.1
Currency translation	0.3
Ending balance	10.8
2015 Restructuring Plans [Member] | Abandonment of Excess Facilities [Member]
Restructuring Reserve [Roll Forward]
Costs incurred	0.1
Payments	-0.1
Currency translation	0
Ending balance	0
2015 Restructuring Plans [Member] | Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Costs incurred	0.9
Payments	-0.4
Currency translation	0
Ending balance	0.5

Additional_Accounting_Policy_a

Additional Accounting Policy and Balance Sheet Disclosures (Details) (USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount Of Derivatives	$6,250	$3,740
Derivatives Designated as Cash Flow Hedges [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Notional Amount Of Derivatives	$1,000

Acquisitionrelated_Intangible_1

Acquisition-related Intangible Assets, Future Amortization Expense (Details) (USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Definite-Lived Intangible Assets, Future Amortization Expense [Abstract]
Definite-Lived Intangible Assets, Net	$12,320.90	$12,808.20

Goodwill_Details

Goodwill (Details) (USD $)	Mar. 28, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Goodwill [Roll Forward]
Beginning balance	$18,732.90	$18,842.60
Ending balance	$18,732.90	$18,842.60

Dispositions_Details

Dispositions (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of businesses, net of cash divested	$0	$1,056.60
Gain (Loss) on Divestiture of Businesses	0	758.5
Current Assets	6,180.50		6,539.80
Current Liabilities	$6,861		$5,349.80

Geographical_Information_Detai

Geographical Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$3,918.80	$3,903.50
Long-lived Assets	$2,384.20		$2,426.50

Pensions_Benefit_Obligations_D

Pensions Benefit Obligations (Details) (Pension Plans, Defined Benefit [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Pension Plans, Defined Benefit [Member]
Change in Projected Benefit Obligation [Roll Forward]
Service costs	$6.20	$4.60
Interest costs	$19.40	$20.10

Pensions_Plan_Assets_Excluding

Pensions Plan Assets Excluding FV Disclosures (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Defined Benefit Plan Disclosure [Line Items]
Cash contributions to retirement plans	$18	$18.80

Income_Taxes_Components_Detail

Income Taxes Components (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Components of Income From Continuing Operations Before Income Taxes [Abstract]
Income from Continuing Operations Before Income Taxes	$382	$774.40
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Provision for Income Taxes	-3.1	231.3
Excess income tax benefits from stock-based compensation plans recognized in equity	$39	$48.20

Unaudited_Quarterly_Informatio

Unaudited Quarterly Information (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 28, 2015	Mar. 29, 2014
Unaudited Quarterly Information [Abstract]
Revenues	$3,918.80	$3,903.50
Net income	385.1	543.1
Earnings per Share
Basic (in dollars per share)	$0.97	$1.38
Diluted (in dollars per share)	$0.96	$1.36
Cash Dividends Declared per Common Share (in dollars per share)	$0.15	$0.15
Total Restructuring and Other Costs (Income), Net	$40.20